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Abstract 
Breast cancer is the most common cancer in women and the main reason of cancer death in the 
less developed countries. Metastasis is the leading cause of death in breast cancer patients. Due 
to the complexity of this cascade, many aspects of metastasis are still unknown and we still lack 
therapy to cure or prevent metastatic breath cancer. Differences in tumor microenvironment 
influence tumor characteristics. Infiltrated immune cells play an important role in cancer related 
inflammation and may promote metastasis. Macrophages are member of innate immunity and 
represent a major component of infiltrated cells within solid tumors. They can be classified to 
classically activated macrophages (M1) and alternatively activated macrophages (M2). Tumor 
associated macrophages (TAMs) contribute in initiation and progression of tumors and are 
predominantly M2 macrophages. 
Animal models have been developed for studying function of macrophages in the tumor 
microenvironment. However, designing in vitro models that may mimic interaction between 
cancer cells and macrophages could simplify the studies of the multiple interactions in the tumor 
environment and may lead to better understanding of metastatic cascade. This study was 
focused on a syngeneic mouse model with a functioning immune system. A model of two 
BALB/cfC3H mouse cell lines, 66cl4 and 67NR isolated from the same primary tumor but with 
a different metastatic potential was chosen. Analyzes of transcriptome sequencing data obtained 
from the cell lines grown in culture and as tumors in mice demonstrated numerous transcripts 
present in the tumor but lacking in the cell lines. These differences in the transcriptome 
indicated several types of stroma cells recruited into the tumors. Comparing two mouse 
mammary primary tumors, 66cl4 (metastatic) and 67NR (non-metastatic), suggested that 
almost 40% of 66cl4 and 30% of 67NR primary tumors are consist of non-tumor cells. M2 
macrophages are known for their contribution in breast tumor metastasis and progression. 
Presence of M2 macrophages in 66cl4 primary tumor, may correlates with metastatic potential 
of this primary tumor. In an attempt to mimic the interaction between the two cancer cell lines 
and immune cells, the macrophage cell lines RAW264.7 and IC-21 cell line was tested. The 
obtained results suggest that these two transformed macrophage cell lines are not responsive to 
signal emerging from the cancer cells. This study suggests that RAW264.7 and IC-21 cell lines 
cannot be ideal models for studying this interaction but that primary macrophages represents a 
better option for studies of how cancer cells may regulate normal macrophage function. 
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1. Introduction 
Breast cancer is the most common cancer in women. The prevalence have increased during the 
past years (1). Based on American Cancer Society statistics from 2013, one in eight women in 
the United States suffer from breast cancer during her life (2). Breast cancer is the main reason 
of cancer death among women in the less developed countries (3). In Norway 645 deaths was 
reported to the Cancer Registry of Norway in 2012 (4). Breast cancer is a heterogeneous and 
complex disease to study and cure (5).  
 
1.1 Cancer Biology 
Hanahan and Weinberg (6, 7) described common changes in cancer cells as “Hallmarks of 
cancer” that includes: Sustaining proliferative signaling, evading growth suppressors, resisting 
cell death, enabling replicative immortality, inducing angiogenesis, and activating invasion and 
metastasis. In addition to genome instability, inflammation promotes development of these 
hallmarks function. Moreover, reprogramming energy metabolism and evading immune 
destruction are emerging hallmarks (7). 
Autophagy is an intracellular system for degrading damaged or extra proteins and organelles. 
It exists in a basal level in all cells for viability and homeostatic maintenance. In nutrient poor 
conditions, autophagy serves as a source of energy. Autophagy can have a paradoxical role to 
both suppress and promoting tumor growth in a context dependent manner. In nutrient 
starvation and hypoxic conditions, autophagy can be elevated in tumor cells and increase tumor 
survival (8). 
Mutation in proto-oncogenes which is followed by their activation and loss of function of a 
tumor suppressor genes is obligatory in cancer development (9). Multiple biological steps are 
required during development of tumors. Sequential accumulation of somatic changes in 
preneoplastic and neoplastic cells lead to uncontrolled cellular growth, proliferation, invasion 
and metastasis (10). Furthermore, tumor progression depends on cellular genomic, epigenetic 
status (9) and also the tumor microenvironment at each stage of the tumor development. The 
extracellular matrix (EMC), stromal cells and infiltrating cells like immune cells constitute a 
complex heterogeneous tumor microenvironment. These cells secrete numerous chemokines, 
growth factors and matrix degrading proteins, which support tumor development(11).  
 
Introduction 
2 
 
1.1.1 Breast cancer classification 
Due to the complexity and heterogeneity of breast cancer, there are three classifications for this 
disease: histopathological, biological and molecular classification. Histopathological 
classification is based on morphological characteristics and divides breast tumors to two main 
categories: invasive ductal carcinomas (IDCs) and invasive lobular carcinoma (ILC) (12). A 
week point of this classification is its minimal prognostic prediction (12). Biological 
classification is focused on prediction of responses to systematic interventions and is basically 
practical for clinical use. Based on this classification tumors are subdivided to highly endocrine 
responsive, not endocrine responsive and uncertain endocrine responsive (12). Breast cancer 
gene expression profiling in different studies ended up to molecular classification (13). This 
classification is subdivided to four groups that are variant in gene expression pastern, clinical 
features of treatment response and outcome. Luminal A and luminal B group highly express 
hormone receptors and associated genes. The HER2 group is characterized with high expression 
of HER2 (human epidermal growth factor receptor 2) and low expression of ER (estrogen 
receptor) and associated genes. Almost 15 percent of invasive breast cancers are of the basal-
like group. This group is defined with high expression of basal epithelial genes and low 
expression of ER and HER2. Breast cancers classified in this group are mostly triple negative 
(ER/PR(progesterone receptor )/HER2) and are generally associated with poor prognosis (13). 
 
1.1.2 Tumor heterogeneity 
Breast cancer is a heterogeneous disease with high degree of functional, intra and intertumoral 
variety. These factors are critical in both tumor progression and therapeutic resistance (14). 
Basically, tumor heterogeneity is consist of intertumoral heterogeneity (molecular differences 
between patients), intratumoral heterogeneity (gain or loss of genomic alteration of tumor cells 
within metastatic cites), intratumoral spatial heterogeneity (somatic mutations or copy number 
changes within a tumor), tumor initiating ability (functional heterogeneity) and metastatic 
capacity (15). 
 
1.1.3 Tumor invasion and metastasis 
Metastasis is the main cause of cancer mortality and develops in the most severe forms of breast 
cancer (16). Novel techniques such as analysis of circulating tumor cells help to diagnose 
metastasis but prevention or treatment of metastatic breast cancer is still challenging (17). This 
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multi-step phenomenon starts with cell de-attachment from a tumor (16). In this process, cell –
cell adhesion and cell adhesion to ECM are modified, allowing cells to detach (18). Free tumor 
cells enter blood or lymphatic vessels (intravasation) and reach distant organs. There, 
extravasation to the organ parenchyma, proliferation and angiogenesis leads to tumor creation 
and survival in a new organ (16, 17). Thus, metastatic cancer cells need to acquire abilities to 
survive in circulation and continue to grow in targeted organs (19). Non-tumorigenic cells may 
aid in the metastasis. It has been reported that platelets support tumor cells from shear stress 
(20) and Natural killer cell (NK) mediated cytotoxicity in blood circulation (21). 
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1.2 Tumor microenvironment 
The tumor microenvironment contributes to make cancer a heterogeneous and complex disease. 
Each tumor is unique regarding molecular constitution, interaction of host and tumor cells and  
tumor microenvironment (22). Tumor microenvironment is composed of extracellular matrix 
(ECM) and normal non-mutated host cells, for instance: mesenchymal, vascular endothelial and 
various inflammatory cells. Cancer cells use their microenvironment as a source of nutrients, 
oxygen, growth factors and cytokines (23). Interaction between tumor cells and 
microenvironment affects primary cancer growth, invasion and metastasis (21). The tumor 
microenvironment is influenced by both endogenous factors (such as genomic variation and 
hormonal environment) and exogenous factors ( dietary, environmental exposure and lifestyle) 
(22).  
 
1.2.1 Extracellular matrix 
ECM acts as a physical scaffold that facilitates cells adhesion, movement and cell-cell 
interaction. It consists of many components including glycoproteins like laminin, fibronectin, 
elastin and fluid produced by cells. All these elements can influence tumor cells in different 
ways (19). Stromal cells like fibroblasts, endothelial cells, adipocytes and different immune 
cells are embedded in ECM (21, 24). It is noteworthy that stromal cells of tumor 
microenvironment are heterogeneous both in their proportion and activation status. These cells 
play diverse functions in different stages of tumor development (21). For example: adipocytes 
which are the most frequent adjacent cells around breast cancer cells (25), provide fatty acids 
which contribute in tumor growth (26). Activated endothelial cells facilitate angiogenesis in 
both primary and metastatic tumor (27) and they can also contribute initiating breast cancer 
(25). Fibroblasts in ECM exist in high number and enhance metastasis in premalignant and 
malignant breast epithelial cells (21). Moreover, fibroblasts in the breast tumor 
microenvironment may induce therapeutic resistance.  It is notable, stromal cells in the breast 
tumor environment can also modify phenotype of the tumor cells (25). For instance, IL6 
secreted from cancer associated fibroblasts induced invasive phenotype in breast cancer (28). 
 
1.2.2 Immune cells  
A complex composition of immune and inflammatory cells exists in tumor microenvironment 
(23). Different bone marrow-derived cells can be seen in the stroma of tumors, including 
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myeloid and lymphoid lineage cells. Typical myeloid cells found in tumors are macrophages, 
neutrophils and myeloid-derived suppressor cells (MDSC) (Figure 1.1) (19). Lymphoid lineage 
cells are also present in tumor microenvironment and demonstrate distinct functions depending 
on their types. For instance, CD8+ cytotoxic T lymphocytes (Tc) induce apoptosis in cancer 
cells by releasing perforin and granzyme (21). T helper type 1 (TH1) cells support Tc cells in 
tumor rejection, while T helper 2 (TH2) cells and regulatory T (TREG) cells cooperate in 
suppressing activation of Tc cells (29). Furthermore, B lymphocytes secrete pro-tumorigenic 
cytokines and alter TH1 and TH2 ratios (21).  
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 1.1: Schematic illustration of the primary cells in the tumor microenvironment 
Tumor microenvironment consists of endothelial cells from blood and lymph, fibroblast and different bone 
marrow-derived cells for example; macrophages, myeloid derived suppressor cells (MDSC), TIE2-expressing 
monocytes (TEMs), mast cells and mesenchymal stem cells (MSCs).These cells are recruited by cancer cells and 
have different functions. The figure is adopted from Joyce, J. A. et al., 2009 (19). 
 
Cancer cells able to form tumors are successful in escaping from immune system and also in 
modifying immune cell types in favor of tumor cells (24). Bone marrow-derived cells, myeloid 
lineage in particular, are recruited to primary and metastatic tumors. They can have opposing 
functions in promoting or inhibiting tumor growth. Chemokines and growth factors such as 
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chemokine (C-C motif) ligand 5 (CCL5)/RANTES and CXCL12/SDF-1 produced by stromal 
and tumor cells recruit monocytes which differentiate to macrophages in the tumor site (30). 
Existence of macrophages in the tumor tissue correlate with poor prognostic, higher tumor 
grade and increased mortality rate (31). 
MDSCs are heterogeneous early myeloid cells that can be generated in response to cancer 
derived factors and cause immune response suppression. These cells produce arginase1 
(ARG1), inducible nitric oxide synthase (NOS2) also known as iNOS and reactive oxygen 
species that create an immune environment which contributes in tumor progression (32). 
MDSCs activation can also protect metastatic cancer cells from Tc cells and NK cells (24, 32). 
Identification of mechanisms and molecular events within breast cancer microenvironment that 
contribute to tumor progression can indicate new therapeutic targets (25). Different cell types 
can be investigated by using cell specific markers. cell markers can be investigated (23). Table 
I shows some markers of immune cells present in breast tumor microenvironment and that can 
be analyzed for experimental purposes (see appendix).  
  
1.2.3 Cancer-related inflammation and infiltrated immune cells 
In 1867, Virchow et al., described the role of inflammation in cancer development (33). Recent 
evidence supports the role of inflammation in breast cancer regulation (34). Harold and Dvorak, 
1986 first described tumors as “wounds that do not heal” (35).Studies have shown that 
inflammation that resulted from tissue injury, promotes cellular proliferation and neoplastic 
transformation (36). Infiltrated immune cells are important players in cancer related 
inflammation (33). Elimination of mature B lymphocytes and subsequent decrease in innate 
immune cells recruitment in a transgenic mouse model demonstrates the role of chronic 
inflammation in promotion of de novo carcinogenesis (37). A wide number of chemokines 
recruit leukocytes to the inflammatory site (33). Macrophages constitute the major 
inflammatory cell type in the stroma of different tumors (38). Increased number and activity of 
macrophages and other MDSC in chronic inflammation is possibly due to the B cells and T 
helper17 (TH17) cells activation (29). These characteristics make it eligible to study the function 
of macrophages as an inflammatory cell that promote cancer progression. 
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1.3 Macrophages  
Circulating monocytes differentiate into macrophage and dendritic cells in body tissues in the 
steady state and in response to inflammation (39, 40). Monocyte-macrophages lineage are well 
known for their diversity and plasticity (30). In the tissues, macrophages can be activated by 
both endogenous and exogenous factors (41). 
Macrophages play a critical role in innate immunity. They are phagocytic cells are recognize 
their target through receptors of the cell membrane (42). A multitude of receptors are expressed 
on the surface of macrophages (39). For instance, scavenger receptors (SRs), such as CD163 
(43), bind to modified lipoproteins (44) on the surface of apoptotic and necrotic cells. These 
receptors opsonize pathogens and cell debris and initiate phagocytosis. Subsequently, 
macrophages engulf opsonized pathogens and debris into a phagosome and digest the 
components. Signaling pattern recognition receptors (PRRs) including toll-like receptors 
(TLRs), NOD-like receptors (NLRs) and retinoic acid-inducible gene 1 (RIG1)-like helicase 
receptors (RLRs) are also expressed on the surface of macrophages. TLRs are able to recognize 
non-self (PAMS) and damaged cells (DAMS) in the cytoplasm or on the cell surface of the cells 
and trigger downstream signaling mechanisms that activates transcriptional mechanisms. This 
process will finally result in clearance of the insult and release of different cytokines and 
chemokines in order to respond to their environment (39). Macrophages can also be activated 
in response to cytokines such as IFN-γ. Anti-inflammatory molecules such as IL4 and IL13 can 
also activate macrophages (45). It is explained in more detail in figure 1.2 and rest of section 
1.3 of the introduction chapter.  
Macrophages are the most common infiltrated cells in the microenvironment of  many tumors 
(46). High number of macrophages in breast tumor stroma correlates with tumor size and 
reduced breast cancer survival (47).  
Macrophages can be classified based on their function. There exists a spectrum of subtypes 
from classically activated macrophages (type I macrophage, M1) (45) to alternatively activated 
macrophages (type II macrophages, M2) as the most extreme samples (Figure 1.2) (45, 48). 
These heterogeneous cells can change their polarization and function in response to different 
environmental signals (49) such as microbial antigen and TH1 or TH2 derived cytokines (45, 
50) and also tumor products (51). The remarkable contribution of macrophages in breast tumor 
progression is the main focus for the current study. 
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Figure 1.2: Macrophages, spectrum of subtypes  
In this figure, molecules that are induced by IFN-γ and LPS (classical activation) are displayed in green (for M1) 
and they express opsonic receptors (such as Fcγ-RI/CD64 and Fcγ-RI/CD32). For M2 macrophages, molecules 
induced by IL4 and IL13 displayed in yellow, IL10 in red and IL4, IL13 and IL1 displayed in blue. M2 
macrophages poses high number of mannose receptor (MS) (modified) (45). 
 
1.3.1 Macrophage phenotypes 
The alternative activation of macrophages was first described in 1992 Stein M et al.,(48). An 
in vitro model evidenced that interleukin 4 (IL4) induces a polarization, distinct from 
macrophages induced by interferon γ (IFN-γ). In this model stimulation of peritoneal 
macrophages with IL4, enhance MR expression and activity compared to macrophages 
stimulated with IFN-γ. Macrophage can be schematically divided to M1 (pro-inflammatory) 
and M2 (anti-inflammatory) (41, 52). Macrophage activation status should be studied as a 
continuum ranging from pro-inflammatory (M1) to anti-inflammatory (M2) rather than discrete 
phenotypes (53). 
Classically activated macrophages respond to pathogens and are important players of the innate 
immune defense (54). Monocytes differentiate to M1 in the presence of exogenous pathogens 
associated molecules like the bacterial Lipopolysaccharide (LPS) (55, 56), endogenous danger 
signals such as heat shock proteins (41) or endogenous cytokines such as IFN-γ (57), tumor 
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necrosis factor (TNF) and granulocyte macrophage colony stimulating factor (GM-CSF) (41, 
56). M1 activated cells can be distinguished by elongated appearance (41). Moreover, M1 
macrophages secrete pro-inflammatory cytokines such as IL23 and IL12 (56). These factors, 
together with phagocytosis, are important for the removal of pathogens and danger signals and 
initiation of an immune response in the early phases of wounds’ healing (58). M1 macrophages 
have anti-tumor activity (59). IL12 secreted from M1 macrophages can suppress metastasis (60) 
and stimulates T cell (61) and NK cell cytotoxicity against tumor cells (62). Nitric oxide (NO) 
produced by macrophages is cytotoxic and plays role in suppression of tumor growth (63) and 
metastasis (64). Binding of LPS to TLR4 on the surface of M1 macrophage leads to NO 
production by NOS2 through NF-κB  activation (65).  
On the other hand, M2 macrophages exhibit anti-inflammatory functions and regulate wound 
healing (39). Monocytes differentiate to M2 in the presence of TH2 cytokines such as 
interleukin 4 (IL4), IL10, IL13 (57, 66) and macrophage colony stimulating factor (M-CSF) 
(41, 56).  IL4 and IL13 cytokines elevate expression of MR by M2 macrophages and stimulates 
in vitro activity of arginase, whereas elevated activity of NOS2 by IFN-γ stimulation inhibits 
arginase activity. Arginase is an intracellular enzyme (66) that regulates wound healing and 
fibrosis. This enzyme inhibits antitumor TC cell response and converts L-Arginine to urea and 
L-ornithine that are main substrates for polyamines production. Polyamines are necessary for 
cell cycle progression (67).  
In vitro stimulated M2 macrophage induces spheroid phenotype (41). Generally, M2 
macrophages promote angiogenesis and contribute in the tissue remodeling and repair by 
release of vascular endothelial growth factor (VEGF), transforming growth factor β (TGF-β) or 
fibroblast growth factor (FGF) in wounds (58). In the tumor micro environment, M2 
macrophages show the same functions in favor of tumor progression (52). This paradoxical role 
of macrophages has not been completely understood (56). A summary of M1 and M2 
macrophage cytokine, their activation and function can be seen in figure 1.3 (68). 
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Figure 1.3: Schematic M1 and M2 macrophages function and activation 
M1 and M2 macrophages modify their function in response to the environmental stimuli. M1 macrophages are 
induced by LPS and IFN-γ and release different proinflammatory cytokines such as IL6 and IL1β. M1 polarized 
macrophage demonstrate antiviral, antimicrobial and tumor resistance function .In contrary, M2 macrophages can 
be induced by IL4 and IL13 and release different chemokines and proangiogenic factors. M2 macrophages can 
contribute in immunosuppression, angiogenesis and tumor promotion (modified) (68). 
 
1.3.2 Tumor-associated macrophages  
Macrophage phenotypes change during the malignancy process. Initially,  M1 macrophages 
induce inflammation around epithelial lesions by secreting TNFα and IL12 (69). Secretion of 
variety of growth factors from M1 macrophages results in high proliferation of epithelial cells 
to replace  damaged cells (70). This high proliferation rate can lead to acquisition of mutations 
in the epithelial cells. Because of hyperplastic lesion progression, intraepithelial neoplasia will 
be formed. Chemo attractants and a variety of chemokines such as CCL-2 recruit monocytes to 
the site of inflammation from blood circulation (71). Recruited monocytes differentiate to 
tumor-associated macrophages (TAM) in the presence of M-CSF released by neoplastic cells 
(72). These macrophages mostly resemble M2 like phenotype (71, 73) and function (74, 75). In 
addition, mouse mammary tumor gene profiling data demonstrated that TAMs are 
predominantly M2 macrophages. 
TAMs have the leading role in cancer-related inflammation. As reviewed by M. Liguori et al., 
TAMs constantly contribute in deposition and degradation of the ECM which results in release 
of matrix-bound growth factors (72). ECM remodeling and basement membrane fragmentation, 
promote tumor cell motility and invasion (76). Down-regulation of adaptive immune system by 
TAMs goes along with production of cytokines such as IL10 and TGFβ. Produced cytokines 
recruit and stimulate TREG  and recruit TH2 lymphocytes that inhibits TH1 activation and induce 
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naive T lymphocytes. TAMs also contribute to angiogenesis by producing proangiogenic 
cytokines (52) such as VEGF and FGF. Some of the cytokines, chemokines and proteases 
associated with tumor angiogenesis, metastasis and immune suppression are summarized in 
figure1.4 (73). However, the function of TAMs in initiation and progression of tumors has not 
been completely understood (77). 
 
 
 
Figure 1.4: TAM function in tumor progression  
TAM contributes in tumor progression. M2 macrophages are predominant in tumor microenvironment. They 
express cytokines, chemokines and proteases that increase tumor metastasis, angiogenesis and immune 
suppression (modified) (73). 
 
1.3.3 Macrophages and tumor energy acquirement 
Tumors growth beyond 1-2 mm in diameter acquires induction of new blood vessels for 
proliferation and metastasis (78-80). Angiogenesis is a process in which capillaries sprout from 
endothelium of the existing vascular networks (79, 81). This process facilitate supply of oxygen 
and nutrients, evacuate metabolic waste and contributes in metastasis (7, 82). It is now well 
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established that breast cancer, as many other types of cancer, is dependent on angiogenesis that 
correlates with invasiveness and poor survival (83, 84). Components of the tumor 
microenvironment are of extreme importance in angiogenesis (85). TAMs influence 
angiogenesis by expression of angiogenic factors such as VEGF (33) and platelet-derived 
endothelial cell growth factors and also TNF-α and IL8 in hypoxic conditions (86). Moreover, 
pericytes that are located on the surface of capillaries contribute in stabilizing vessel wall, 
controlling endothelial cell proliferation and new capillaries growth (87). 
Autophagy is an intracellular degradation system in which breaking down cellular organelles 
results in re-using sources of energy in the cell. This catabolism will be used for biosynthesis 
and energy metabolism. Autophagy is critical during fasting but also removes damaged 
organelles, misfolded proteins and microorganisms from the cytoplasm. It is present in a basal 
level in cells but can also be upregulated in cellular stress such as nutrient deficiency 
representing a survival mechanism in situations of cellular stress (88, 89). Martinez-Outschoorn 
and his colleagues’ experimental model explains that epithelial cancer cells induce autophagy 
in the tumor stroma by oxidative stress and initiate energy transfer from tumor stroma which 
enhances tumor growth (90). They have called this model “Battery-Operated Tumor Growth”  
(91).   
Furthermore, autophagy is important in maintenance and differentiation of hematopoietic stem 
cells (HSCs), differentiation of monocytes into macrophages and also macrophage recruitment 
(92).  
 
1.3.4 Macrophages in Breast cancer 
Plethora of macrophages can be detected in the nipple aspirate of women from reproductive 
age. An experimental model demonstrated that high number of macrophages is recruited to the 
developing terminal end bud (TEB) of the mammary gland of mice. They are abundant in the 
base and shaft of the TEB and can also be found in TEB itself. Notably, collagen fiber network 
facilitate macrophage movement (Figure1.5). Macrophages that are present in mammary gland 
are associated with immune suppression and tumor progression (93). This also correlate with 
poor prognosis(94), increased vascular density(95), tumor size and mortality (47).  
It is now well established that TAMs play a prominent function in breast carcinogenesis (96-
98). They can make up almost half of the breast tumor cell mass (99) which correlates with 
poor prognosis (98, 100). Breast tumors present a hypoxic condition such as many other solid 
tumors (101). This condition enhances macrophage recruitment to the breast tumor 
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environment (102). Recruited macrophages are entrapped in the hypoxic area (103). As Leek 
RD and his colleagues has shown, accumulation of TAMs correlates with angiogenesis in breast 
tumor (104).  
 
 
Figure1.5: Topology on macrophages in TEB  
In mice, TEB is surrounded by fibroblastic stroma and adipocytes. Numerous numbers of immune cells such as 
macrophages are found in TEB. Preferred areas of different cells are indicated (93). 
 
1.3.5 Role of macrophages in breast tumor metastasis  
Breast tumor can metastasize to lung, bone, liver, lymph nodes (19) and pleura (105). TAMs 
enhance breast cancer metastasis by secreting a wide range of cytokines and chemokines (106). 
CCL18 is mostly produced by M2 macrophages, which are the most abundant macrophages in 
breast tumor. CCL18 production in breast tumor correlates with invasion, metastasis and 
reduced patient survival (98). CCL2 is another chemokine which is over expressed in breast 
cancer and associated with high metastatic rate and subsequent increased mortality in mice. 
L.Bonapace and her colleagues demonstrated that treatment by anti-CCL2 reduced 
macrophages in a primary tumor of 4T1.2 cells, derived from BALB/cfC3H mouse (107). 
Moreover, CXCL12 receptor (CXCR4) is expressed on macrophages and tumor cells. Tumor 
cell motility and invasion can be stimulated by production of CXCL12 in the mouse model (71). 
In addition, expression of angiogenesis factors such as VEGF by TAMs, promotes 
vasculogenesis in the breast tumor, which is vital for tumor metastasis (108). This aspect is 
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explained in detail in section 1.3.2. In addition, macrophages help tumor cell egression and 
intravasation by clustering on the blood vessel (71). 
Present treatment options are not effective to cure metastatic breast cancer (109). Hopefully, a 
better comprehension of the metastatic cascade can lead to new therapeutic methods (110). 
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1.4 Model systems of cancer development 
Varity of experimental models can be used in order to study different aspects of the cancer. 
Transgenic mouse models have been used for studying role of a distinct genes in breast 
carcinogenesis (111). For studying effect of different cytokines and growth factors, human 
cancer cell can be studied in cell culture. Cytokines and growth factors can be added to the 
culture and then tumor cell response can be studied. In addition, cancer cells can be co-cultured 
with stromal cells such as fibroblasts. However, results from such models are difficult to 
interpret and components of tumor microenvironment such as immune cells are absent. Using 
human cancer cell lines and implanting the cells in the mouse is another option. In such models 
tumor cells and microenvironment are from different origin, immune cells are missing. 
Therefore, this model is not optimal for studying tumor heterogeneity. Using human patient 
tumor and implanting tumor in an immunodeficient mouse can include original tumor 
heterogeneity and micro environmental compartments such as fibroblast to the model, but 
immune cells are absent in this model as well. In syngeneic spontaneous models, mouse tumor 
cell lines are used, host immune cells are present and microenvironment is intact (112). Immune 
system of mouse is normal and is from the same species with tumor cells. This feature represent 
the real life situation that is important in the studies that are focused on interaction between 
tumor and host microenvironment. However, this model may not represent genetic and clinical 
complexity of human tumors (113). Autochthonous murine tumor models are spontaneous or 
chemical, viral and physical induced tumors that include many tumor micro environmental 
features. This model closely mimic human tumors than transplant tumor models but more 
expensive and with lower throughput. Other disadvantages of this model are stochastic 
variability and lack of spontaneous metastasis (114, 115).  
 
1.4.1 The 4T1 syngeneic BALB/cfC3H mouse breast Cancer Model 
Our laboratory has access to five mouse breast cancer cell lines (67NR, 168FARN, 4TO7, 66cl4 
and 4T1). These cell lines originate from a spontaneous arising BALB/cfC3H mouse mammary 
tumor (116, 117). Their different metastatic ability have been documented in many studies 
(Table1.1) (118, 119). This basal-like model (120) gives a valuable opportunity to study 
interaction of primary tumors and immune cells in a heterogeneous microenvironment by 
designing a syngeneic, non-manipulated mouse model with a functioning immune system.  
Earlier studies by the Bjørkøy group have investigated the autophagic flux of these five breast 
cancer cell lines. Unpublished recent in vitro experiments demonstrated that 66cl4 cell line has 
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higher expression of autophagic markers such as p62 and LC3B-II and higher autophagy flux 
compared to 67NR cell line. No significant expression of autophagic markers in other cell lines 
was observed. Therefore, 66cl4 and 67NR were chosen for further analysis. It was hypnotized 
that the increased autophagy flux of 66cl4 lead to better availability of nutrients under starving 
conditions and thus more aggressive growth and metastasis. As previously mentioned, tumors 
are comprised of different cell types that may contribute to different aspects of carcinogenesis. 
Accordingly, autophagy could be differently regulated in different cell types of the tumor 
microenvironment. Most importantly, the tumors of both cell lines have been RNA sequenced, 
which can represent valuable information regarding gene expression, but also this data does not 
take into account the contribution of different cell types in the tumor. Therefore, it makes an 
obligation of characterizing different cell types in the primary tumor and their composition to 
allow a more precise interpretation of further results. 
   
Table1.1. Metastatic properties of 5 cell lines isolated from a spontaneous arising mammary tumor 
BALB/cfC3H (118, 119) 
Cell line 67NR 168FARN 4TO7 66cl4 4T1 
Primary tumor    Yes   Yes Yes   Yes  Yes  
Metastatic 
potential 
   No Yes Yes   Yes  Yes  
   Micro 
metastases 
to lymph 
nodes 
Micro 
metastases 
to the lung, 
lymph 
nodes, blood 
Lungs lungs, bones, 
lymph nodes, 
blood, liver, 
brain, 
stomach etc 
-      + +(+) +++ ++++ 
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1.5 Aim of the study 
The tumor microenvironment plays a prominent function in carcinogenesis and TAMs are an 
important component of the tumor stroma (96, 97). A better understanding of district functions 
of mammalian immune system in both suppression and progression of breast tumors can help 
to define the interplay between immune cells and breast cancer progression. 
The aim of the present study was to investigate BALB/cfC3H mouse spontaneous breast tumor 
model heterogeneity. The first important step was to estimate the number of normal, non-
transformed cells present in primary tumors of 66cl4 and 67NR cells. Secondary, it was of 
interest to determine if macrophages were present in the tumor and try to define their phenotype. 
If signs of differences in macrophage phenotype could be found, attempts to design an  
in vitro model to study the interaction between the macrophage and cancer cell lines should be 
initiated. 
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2. Material and methods 
2.1 Equipment 
Microtome Leica RM2235 Leica Microsystems, Germany 
Confocal microscope LSM 510 Meta  Zeiss, Germany 
EVOS® FL Auto Cell Imaging System Life technologies, USA 
Zeiss Primo Vert Inverted Microscope Zeiss, Germany 
Odyssey CLx 9140 scanner  LI-COR, USA 
Z1 COULTER COUNTER Beckman coulter, USA 
Spectronic GENESYS 20 Visible 
Spectrophotometer 4004-2 
Thermo electron cooperation, USA 
NanoDrop 1000 Spectrophotometer Thermo Fisher Scientific, USA 
Thermal cycler C1000 Bio-Rad Laboratories, USA 
Thermal cycler 2720 Applied Biosystems, Thermo Fisher 
Scientific, USA 
StepOnePlus Real-Time PCR system, 
version 2.0.46 
 
Applied Biosystems, Thermo Fisher 
scientific, USA  
2.2 Consumables 
Chamber Coverglass (#155411) Nunc, Thermo Fisher, USA  
Dako pen (#S200230) Dako, Denmark A/S  
Immobilon-p PVDF Transfer Membrane 
(#IPVH304Fo) 
Millipore, USA  
MS MACS separation columns (#130-042-
201) 
Miltenyi Biotec, Germany  
NuPAGE® Novex® 10% Bis-Tris Protein 
Gels, 1.0 mm, 10 well (#NP0301BOX) 
Life technologies, USA  
NuPAGE® Novex® 12% Bis-Tris Protein 
Gels, 1.0 mm, 12 well (#NP0342BOX) 
Life technologies, USA  
NuPAGE® Novex® 4-12% Bis-Tris Protein 
Gels, 1.0 mm, 12 well (#NP0321BOX) 
 
Life technologies, USA  
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Superfrost Plus microscope slide 
(#4951PLUS4)  
 
Thermo Fisher Scientific, USA 
2.3 Buffers, media and solutions 
20xMOPS SDS running buffer (#NP0001-
02) 
Life Technologies, USA  
Bio-Rad Protein Assay Dye Reagent 
Concentrate (#500-0006) 
Bio-Rad Laboratories, USA  
Blood and cell culture DNA mini kit 
(#13323) 
Qiagen, Netherland  
cOmplete, EDTA-free (#11873580001) Roche, Switzerland  
Dako Target Retrieval Solution (#S169984-
2) 
Dako, Denmark A/S  
Dimethyl sulfoxide (DMSO) (#D2650) SIGMA-ALDRICH, USA  
DL-Dithiothreitol (DTT) (#45-43816-
50ML) 
SIGMA-ALDRICH, USA  
DRAQ5 (#4084) Cell Signaling technology, USA  
Dulbecco's Modified Eagle's 
medium(DMEM) (#D5796) 
SIGMA-ALDRICH, USA  
Dulbecco's phosphate buffered saline 
(DPBS) (#D8537) 
SIGMA-ALDRICH, USA  
Fetal bovine/calf serum (FBS)/(FCS) 
(#1027) 
Gibco, Life technologies , USA  
Gentamicin (#157100-049) Gibco, Life technologies , USA  
ISOTON II (#854619) Beckman coulter, USA  
L-Glutamine (#17-605E) Lonza, Switzerland  
LPS-EB Ultrapure (#tlrl-3pelps) Invitrogen, USA  
Non-essential-amino acid solution 100x 
(#M7145) 
SIGMA-ALDRICH, USA  
NuPAGE® LDS Sample Buffer (#NP0007) Thermo Fisher Scientific, USA  
NuPAGE® Transfer Buffer (#NP0006-1) Life Technologies, USA  
Odyssey two-color protein molecular weight 
marker(IR dye 400) (# 928-40000) 
LI-COR Biosciences, USA  
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Odyssey® Blocking Buffer, TBS (# 927-
50000) 
LI-COR Biosciences, USA  
Paraformaldehyde 16% (PFA) (#43368) Alfa Aesar, USA  
Penicillin-Streptomycin (#P0781) SIGMA-ALDRICH, USA  
Phosphatase inhibitors cocktail 2 (#P5726) SIGMA-ALDRICH, USA  
Phosphatase inhibitors cocktail 3 (#P0044) SIGMA-ALDRICH, USA  
QuantiTect Reverse Transcription Kit 
(#205311) 
Qiagen, Netherland  
QuantiTect SYBR green PCR kit (#204141) Qiagen, Netherland  
Recombinant Murine IFN-γ (#315-05) Peprotech, USA  
Recombinant Murine IL4 (#214-14) Peprotech, USA  
RNA protect cell reagent (#76526) Qiagen, Netherland  
RNAprotect Cell Reagent (#74624) Qiagen, Netherland  
RNeasy Micro kit (#74004) Qiagen, Netherland  
RPMI-1640 Medium (#R8758) SIGMA-ALDRICH, USA  
TaqMan genotyping master mix (#4371355) Life technologies, USA  
Triton x-100 (#T8787) SIGMA-ALDRICH, USA  
Trypsin-Versene (EDTA) mixture (1X) 
(#BE17-161E) 
Lonza, Switzerland  
Urea (#U5378) SIGMA-ALDRICH, USA  
Vectashield, mounting medium with Dapi 
(#H-150)  
 
Vector Laboratories, UK  
2.4 Computer programs 
GraphPad   
Image Studio LI-COR Inc., U.S.A 
ND-1000 version 3.2.1 Thermo Fisher Scientific, USA 
Step one versions 2.2 and 2.3 Life Technologies, USA 
ZEN versions Blue and Gray 
 
Zeiss, Germany 
2.5 Cell lines 
66cl4  Barbara Ann Karmanos Cancer Institute 
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67NR Barbara Ann Karmanos Cancer Institute 
IC-21   
Raw 264.7  
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2.6 Primary tumors  
This project was focused on analyzing 66cl4 and 67NR primary tumors. 66cl4 and 67NR mouse 
breast tumor cells (500,000 cells per animal) have been injected in to the fat pad of 
BALB/cfC3H mouse. After 3-4 weeks tumors were 1-1, 5 cm and large enough to be removed 
from the mouse. Primary tumors that resulted from this stage have been used for mRNA 
sequencing in Bjørkøy group and protein and DNA isolations in this master study. 
This procedure has been done two times. For the second round, 66cl4 and 67NR cell lines that 
have injected to the mouse had been infected with Mission TRC2 Control Transduction Particle 
puro TurboFFP shRNA (Sigma #SHC204V) to stably express GFP in the tumors. Obtained 
tumors have been used for tumor section preparation. For this purpose tumor samples were 
fixated in 4oC formalin for 1 day and then they have been stored in 70% ETOH /PBS and 
paraffin embedding.  
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2.7 Cell culture 
67NR and 66cl4 
67NR and 66cl4 are adherent BALB/cfC3H mouse cell lines established from a primary breast 
tumor. These cells were cultured according to the guideline that is provided by Barbara Ann 
Karmanos Cancer Institute. Dulbecco's Modified Eagle's medium (DMEM) has been suggested 
by aforesaid institute for maintenance of these cell lines. Based on the Karmanos Cancer 
Institute guideline, medium was supplemented with 10% fetal bovine serum (FBS), 1% L-
glutamine, 1% Non-essential amino acid solution and 1% Penicillin/streptomycin. 
 
RAW 264.7 
RAW 264.7 cells are mouse-derived macrophages that have been established from a tumor 
induced by Abelson murine leukemia virus (ATCC® TIB-71™). This adherent cell line was 
cultured in RPMI-1640 medium supplemented with 10% fetal bovine serum (FBS), 1% L-
glutamine, 1% Non-essential amino acid solution and 1% Penicillin/streptomycin.  
 
IC21 
IC-21 is an adherent cell line that was established by transformation of normal C57BL/6mouse 
peritoneal macrophages with SV40 virus. It demonstrates many characteristics of normal mouse 
macrophages such as phagocytic and cytolytic properties. This cell line has been provided in 
cooperation with CEMIR and was cultured based on ATCC guidelines (ATCC® TIB-186™) 
in RPMI-1640 medium. This medium was supplemented with 10% fetal calf serum (FCS), 
0,034 % L-Glutamine and 1% gentamicin. Medium of these adherent cells should be changed 
3 times a week due to the high acid production. 
 
2.7.1 Taking up the cells 
Cells have been kept in a cryotube in 20% FBS and 10% DMSO in the liquid nitrogen storage 
container. They were thawed in 37oC water bath. Cells were taken up in 5-10 ml medium and 
were transferred to a 15 ml tube. After centrifuging in 1500 rpm for 5 minutes, 5ml cell line 
specific medium was added to the cells. Dissolved cell pellet was transferred to a 25cm2 culture 
flask with 5ml medium and placed in a 5%CO2 humidified incubator at 37oC. Medium was 
changed after the cells had attached. Cells were routinely kept in the incubator, which provides 
optimized condition for cell growth. 
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2.7.2 Subcultivation of cells 
Subcultivation was after cells reached 70-80% confluency by removing the old medium, 
washing the cells twice with phosphate buffered saline (PBS). For detaching 66cl4 and 67NR 
cell lines, trypsin added and for RAW264.7 and IC21 cells PBS plus 0,02% EDTA was added. 
It was followed by addition of specific medium for each cell line. Suitable number of cells was 
added to a new culture flask filled by adequate medium. For running a new experiment, cells 
were ready after subcultivateed for three times. The cell line which was subcultivated for more 
than 20 passages was discarded. 
 
2.7.3 Conditioned medium preparation 
Conditioned medium of 66cl4 and 67NR cells was prepared from two different cell passage 
numbers. Cells were counted by adding cell suspension (20µl) to isoton II diluent (10ml) 
(Beckmann coulter) using Z1 Beckman cell and particle counter (Beckmann coulter). Adequate 
number of cells (200.000) were seeded in 6cm dishes (9.5cm2). Cells were left in an incubator 
for 48 hours. Medium of the plate was collected and centrifuged at 1500g for 10 minutes. 
Supernatant was aliquoted to 1.5 ml eppendorf tubes.  
 
2.7.4 Preserving Cells in Liquid Nitrogen 
Cells were washed with PBS and detached using PBS-0.02% EDTA or trypsin. Medium was 
added to detached cells then cells were suspended and counted. Three millions of 66cl4, two 
millions of 67NR and RAW264.7 cells were centrifuged in 1500rpm for 5 minutes. Cell pellet 
was resuspended in the freezing medium containing 20%FBS and 10%DMSO. Cryotubes 
containing 500µl of the cell suspension were incubated in styropore box at -80oC for 48 hours 
before transferring to the liquid nitrogen tank. 
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2.8 Confocal microscopy 
Confocal laser scanning microscopy (CLSM) is based on molecule excitement and subsequent 
emitted florescent. CLSM is consist of a laser light with a defined wavelength which produce 
a beam of light that directed to the specimen and can be detected and converted to a electrical 
signal that creates a photo. As it is illustrated in figure 2.1  pin hole that was embedded in this 
microscope allows only beams from the focal plane to reach the detector which leads to 
production of images with great resolution (121).  
 
 
Figure 2.1: Pinholes function in confocal microscope. Small pinhole designed in confocal microscope allows 
only beams from the focal plane to reach the detector. Therefore, absence of stray light gives a clear image (121). 
 
2.8.1 Seeding and fixating cells  
Cells were counted and appropriate amount of cells were seeded in in a Chambered cover glass. 
Afterwards cells were treated by desired concentration of conditioned medium of 66cl4 and 
67NR (section2.7.2) or ligands (LPS) and cytokines (IFN-γ, IL4) after cells attachment to the 
surface at relevant time points. Cells were fixated adding 4% paraformaldehyde (PFA) to the 
medium and left on shaker for 10 minutes at room temperature. Fixated cells were washed once 
with PBS.  
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2.8.2 Immunostaining 
Before staining cells should be permeabilized, therefore 400µl ice-cold methanol was added to 
the wells. Chambered cover glasses were incubated on ice for 10 minutes and washed once with 
PBS. Permeabilization was followed by blocking in order to reduce non-specific binding. 
Therefore, PBS with 3 % goat serum (200µl/well) was added because goat secondary antibodies 
was used. Cells were incubated in blocking buffer at 4oC on shaker, overnight.  
Both primary and secondary antibodies were diluted in PBS with 1 % goat serum. Primary 
antibodies (150µl/well) were added and incubated on shaker at 4oC overnight or room 
temperature for1 hour (Table2.1). Negative controls contained no primary antibody. Cells were 
washed 6x5 minutes on shaker using PBS (200 µl) and incubated 60 minutes at room 
temperature on shaker with diluted secondary antibodies (150µl/well) (Table2.2). Wells were 
covered from this step to protect light sensitive secondary antibodies. Incubation with 
secondary antibodies was followed by 6x5 minutes washing using PBS (200 µl/well) in 6x5 
min. Nuclei was stained using DRAQ 5 (100µl/well) nuclear stain diluted 1:1000 in PBS and 
followed by incubating at room temperature for 10 minutes. Stained cells were washed once in 
PBS (200) µl and stored in 400 µl PBS at 4oC.  
 
Table 2.1: Primary antibodies for confocal microscopy 
Antigen  Primary antibody Manufacturer Dilution 
NOS2 Rabbit Millipore, USA (#ABN26) 1:1000 
Arginase Chicken Millipore, USA (#ABS535) 1:1000 
 
Table 2.2: Secondary antibodies for confocal microscopy 
Secondary antibody Manufacture Dilution 
Goat anti-rabbit IgG- Alexa 555 Life technologies, USA (#A-11034) 1:5000 
Goat anti-chicken IgG- Alexa 488 Life technologies, USA (#A-11030) 1:5000 
 
2.8.3 Imaging  
Detection on the Zeiss confocal florescent microscope (figure2.1) was performed using ZEN 
2012 (blue edition) with identical adjustment. 
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2.9 Immunofluorescence Staining  
Near-Infrared (NIR) Immunofluorescence (IF) is used in pathology in order to detect and 
localize antigens in formalin fixed paraffin embedded (FFPE) slides. NIR florescent dyes with 
the defined absorption and emission wavelength in the near infrared spectra between 680 and 
800 nm are used. It can be applied for multicolor imaging. In indirect IF, a primary antibody 
that is specific for the molecular of interest is used. A secondary antibody which is tagged to 
IR680/800 (Florescent dye) binds to the antigen of interest. This technique is more sensitive 
compared to direct immune florescence, and there is also an amplification of the signal due to 
the attachment of more than one secondary to each primary antibody. This technique enables 
quantitative analysis by using Odyssey infrared imager.  
Stained sections of 67NR and 66CL4 primary tumors were also analyzed by Zeiss confocal 
florescent microscope based on Abcam protocol by using secondary antibodies that can be 
detected in the visible light spectra.  
 
2.9.1 Preparation of tumor Sample Sections 
The Leica RM 2235 microtome was used to prepare sections from 66cl4 and 67NR primary 
tumor tissue blocks (paraffin embedded tumor sample). Tissue blocks were kept on the ice one 
hour before cutting and after cutting 10 sections from the block. Thickness was set to 4 µm. 
Sections were placed in the 42oC water bath immediately. Stretched sections were placed on 
the superfrost glass slides and kept in a 60oC incubator for 25-30 minutes. Fixed sections were 
stored in -20 for later staining. 
 
2.9.2 Pre-treatment of sections 
Tumor slides were incubated at 65oC for 10 minutes in order to remove paraffin as paraffin can 
interfere the staining. Then they were incubated 2x5minutes in xylol. Slides were rehydrated in 
absolute, 96% and 80% ethanol. So Slides were immersed shortly 3-5 times in each ethanol 
concentration. Afterwards slides were rinsed with cold running tap water for 3-5 minutes. 
Dako Retrieval Solution with pH 9 was diluted by adding 325ml dH2O to 35mL 10x Dako 
stock solution. Retrieval reagent procedure improves deparaffinization, rehydration and 
specific antibody binding. Dako buffer was boiled by jet stream microwave while slides were 
pre-warmed in water tap at the same time. Slides were placed in the buffer while it was boiling 
and they were boiled together for 10 minutes using jet stream. Afterwards slides were cooled 
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down in cold running tap water for 30 minutes. Cooled slides were blocked with 500µl blocking 
buffer dilution for 40 minutes. Blocking buffer boosts sensitivity of the technique and improve 
signal to noise, was prepared by mixing 1:1 odyssey blocking buffer with TBST. TBST was 
made of Tris buffered saline (TBS) with 0.1% Tween-20. 
For blocking tissue samples that were analyzed with confocal microscope, slides were blocked 
with 10% Bovine serum albumin (BSA) in TBST. Subsequently, slides were placed in the 
humidity slide box while it was on the top of the container filled with hot water. Two straight 
lines were drawn on the outer border of the tissue sections with Dako pen to reduce the volume 
of the blocking buffer and the antibody dilutions and avoid drying out the slides 
 
2.9.3 Staining of the Sections 
Blocking buffer was removed and primary antibody solution (100µl/slide) was applied. 
Dilution series for primary antibodies were prepared by in blocking buffer for optimizing 
dilution of primary antibodies (1:50, 1:100 and 1:200) (Table 2.3.). For samples that were 
analyzed with confocal microscope, primary antibodies were diluted in 1% BSA in TBST 
(Table2.4.). For negative control respective section was incubated with blocking buffer instead. 
Simport humidity slide box was used for incubation of slides that was filled with dH2O to 
reduce dryness. Incubation of slides with primary antibodies for 16 hours at 4 degree was 
followed by 4x 5minutes washing with TBST while samples that were analyzed with confocal 
microscope were washed 4×5minutes with TBS.  
Odyssey Li-COR secondary antibodies were diluted 1:1000 with 1:1 Odyssey Blocking Buffer 
with TBS (table2.3) while confocal secondary antibodies were diluted 1:5000 in TBS (table 
2.5). Slides were incubated for 40 minutes in the dark humidity box at room temperature while 
it was placed on a sink full of hot water in order to avoid dryness and dye bleaching. Diluted 
secondary antibodies (100µl/slide) were applied. Slides were located in a dark place from this 
step.  
Slides were wash 4x 5minutes with TBS since tween can increases the background. Then 
stained sections were mounted with a drop of vectashield mounting medium containing Dapi 
and covered with coverslip. Slides were stored in the darkness at 4 degree until vectashield 
hardness. 
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Table2.3: Antibodies for NIR Immunofluorescence staining 
Antigen  Primary 
antibody 
Manufacturer Odyssey Li-COR secondary 
antibody 
Arginase-1 Chicken Millipore(#ABS535) Chicken 800 nm 
NOS2 Rabbit Millipore(#ABN26) Rabbit 680 nm 
  
Table 2.4: Primary antibodies for confocal microscopy 
Antigen  Primary antibody Manufacturer Dilution 
CD68 Rat AbD serotec, USA (#MCA1957) 1:50 
GFP Rabbit abcam, UK (#ab290) 1:200 
 
Table 2.5: Secondary antibodies for confocal microscopy 
Secondary antibody Manufacture Dilution 
Goat anti-rat IgG- Alexa fluor,555 A-21434, Life technologies, USA 1:5000 
Goat anti-rabbit IgG- Alexa fluor,488 A-11034, Life technologies, USA 1:5000 
 
2.9.4 Scanning of the Sections  
Slides were scanned using Odyssey CLx infrared imaging system that can detect the florescent 
dye attached to the secondary antibody. Image Studio software was used for analyzing images 
with the setting that is mentioned in table2.6. Slides that were stained based on Abcam protocol 
for confocal microscopy analysis were monitored using Zeiss confocal florescent microscope 
and ZEN 2012 (blue edition) with identical adjustment.  
 
Table2.6: Image Studio setting for scanning Sections 
Intensity 800 8.0 
700 6.0 
Focus offset (f) 1.0 mm 
Quality(Q) Highest 
Resolution(R) 21µm 
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2.10 Western Blot analysis 
In western blot, also called immunoblotting, denatured proteins are separated based on their 
size. Proteins are either positive or negative charged based on their amino acid composition. In 
this technique, DL-Dithiothreitol (DTT) is applied as a reducing agent to disrupt tertiary 
conformation of proteins by reducing disulfide bands. DTT also distribute negative charge 
evenly on proteins. Polypeptides migrate from negative anode to positive cathode using power 
supply. Therefore, smaller proteins migrate faster. Polypeptides are separated using a 
polyacrylamide gel which isfollowed by transferring to a PVDF membrane. Appropriate gel 
was selected based on the well and pore size. Blotted membrane was stained by using antibody 
of protein of interest. A standard ladder (Odyssey two-color protein molecular weight marker) 
was used determining weight of the protein of interest. 
 
2.10.1 Protein concentration measurement  
Cells were counted by using Z1 Beckman cell and particle counter. Appropriate amount of cells 
were seeded in 6cm dishes or in a six-well plate (9.5 cm2). Cells were treated by desired 
compound with appropriate concentration after cells attachment to the surface at relevant time 
points. Medium movement from the dishes/plates was followed by washing twice with PBS. 
Cell extract was made by adding 40µl 8M urea lysis buffer to six-well and 80 µl to 6cm dish 
followed by scraping the cells from the surface.  Lysis buffer was composed by adding urea 
(8M), Triton-X, dithiothreitol (DTT) (reducing agent), protease inhibitor (25x complete) and 
phosphatase inhibitors (PIC2 and PIC3) as indicated in the table 2.7. 
 
Table2.7: Urea lysis buffer components and concentrations 
8 M Urea LB Concentration In buffer 500 µL 
Urea 60,06 g/mol 8 M 
410 µL 
Triton-X 100 % 0,50 % 
DTT 1 M 0,1 M 50 µL 
25x complete 25 X 1 X 20 µL 
PIC2 (cold) 100 X 2 X 10 µL 
PIC3 (cold) 100 X 2 X 10 µL 
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Suspension was transferred to a 1.5 ml eppendorf tube and mixed by vortexing 3×15 seconds. 
Non-protein components were pelleted by centrifugation for 15 minutes, 15 000 g, at 4oC. 
Supernatant was transferred to a new eppendorf tube. Protein extract was cryopreserved with 
liquid nitrogen and stored at -80oC. 
Protein concentration of the extracts was measured by using Bio-Rad Protein Assay. Bio-Rad 
Protein Assay solution Bio-Rad Protein Dye Reagent Concentrate was diluted 1:5 with MiliQ 
water. Samples were diluted 1:1000 with the Bio-Rad solution and urea lysis buffer was used 
as a blank instead of protein. Samples were mixed by vortexing and left at room temperature 
for 10 minutes. Sample absorbance was measured by using a spectrophotometer (Shimadzu) at 
595nm. Protein concentration was calculated in µg/µl with the equation below: 
 
𝑃𝑟𝑜𝑡𝑒𝑖𝑛 𝑐𝑜𝑛𝑐𝑒𝑛𝑡𝑟𝑎𝑡𝑖𝑜𝑛 [µg/ml] = 𝑂𝐷595 𝑚𝑒𝑎𝑛 𝑣𝑎𝑙𝑢𝑒 × 22 × 𝑑𝑖𝑙𝑢𝑡𝑖𝑜𝑛 𝑓𝑎𝑐𝑡𝑜𝑟/100 
 
2.10.2 Gel electrophoresis 
Running buffer was made by adding 950ml deionized water (dH2O) to 50ml 20xMOPS SDS 
running buffer. Protein samples were diluted according to measured protein concentration in 
10mM Tris-HCl (pH 8.0) in order to make equal protein concentration in all samples. Sample 
buffer was prepared by adding 4xLDS sample buffer to 1M DTT. Then samples were placed in 
an 80oC heating block for 10 minutes. Odyssey ladder IR Dye 4000 was diluted in loading mix 
that was prepared by adding 4xLDS to 10mM Tris-HCl (pH 8.0). 
Proteins were separated using premade 10%, 12% or 4-12% polyacrylamide gel. 
Electrophoresis gel- cassette was placed in the Xcell SureLock Mini-cell. Running buffer was 
added to the cassette. Equal amount of protein samples were loaded to the wells. For protein 
separation 200 volts (V) was applied for 60 minutes.   
 
2.10.3 Membrane transfer using XCell II blotting system (Wet transfer) 
Separated proteins were transferred to a PVDF membrane (pore size is 0.45 µm, >20 kDa). 
Membrane was hydrated in methanol, rinsed in dH2O and placed in transfer buffer before use. 
Transfer buffer was made by adding 425ml dH2O to 25ml 20xTransfer buffer and 50ml 
methanol. Blotting pads were also placed in transfer buffer before use. Afterwards, membrane 
was placed on the top of the gel, surrounded by filter papers and blotting pads (Figure2.3). 
Proteins were transferred at 30 V for 90 minutes. 
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Figure 2.2: Schematic wet blot transfer system. Proteins transfer from gel matrix to nitrocellulose membrane 
using wet (Tank) transfer in the “transfer sandwich”. This system is pressed together using Xcell SureLock Mini-
cell and placed vertically in a tank between steel/platinum wire electrodes (cathode and anode) and filled with 
transfer buffer. Electrical flux from anode to cathode results in protein transfer from gel to the membrane. This 
system is placed in the ice pack or at 4oC (illustration by author). 
 
2.10.4 Membrane blocking and immunostaining 
For preparing blocking buffer the same volume of Odyssey blocking buffer was added to TBST. 
Membrane was blocked for one hour at room temperature on a roller plate at 50rpm. Primary 
and secondary antibodies were diluted in blocking buffer. Membrane was stained with primary 
antibody (Table 2.8) overnight at 4oC on a roller plate at 50rpm, and with secondary antibody 
(Table 2.9) for one hour at room temperature on a roller plate at 50rpm. After staining with 
primary antibody membrane was rinsed with TBST 3x10minutes, after staining with secondary 
antibody it was washed with TBS 3x10minutes. All membrane were stained for ACTB as a 
loading control.  
Proteins were detected using Odyssey CLx infrared imaging system and Image Studio software. 
 
Table 2.8.Primary antibodies for western blot staining 
Antigen Primary antibody Manufacturer Dilution 
β-actin Mouse abcam, UK (#ab6276) 1:1000 
iNOS Rabbit Millipore, USA (#ABN26) 1:1000 
Arginase-1 Chicken Milllipore, USA (#ABS535) 1:1000 
Arginase Goat abcam, UK (#ab60176) 1:1000 
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Table 2.9.Secondary antibodies for western blot staining 
Secondary antibody Manufacture Dilution 
Goat anti- mouse IgG- IRDye 680 LI-COR Bioscience, USA (#926-68070) 1:20.000 
Goat anti-rabbit IgG- IRDye 680 LI-COR Bioscience, USA (#926-68071) 1:5000 
Goat anti-rabbit IgG- IRDye 800 LI-COR Bioscience, USA (#926-32211) 1:5000 
Donkey anti-chicken IgG- IRDye 800 LI-COR Bioscience, USA (#926-32218) 1:5000 
Donkey anti-goat IgG- IRDye 680 LI-COR Bioscience, USA (#926-68074) 1:5000 
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2.11 Quantification of mRNA gene expression using Real-time PCR 
Quantitative Real-time polymerase chain reaction (RT-qPCR) quantifies a specific nucleic acid 
sequence by detecting and measuring amount of mRNA in a given sample, generating copies 
of the template nucleic acid sequence and measuring emitted florescence during each cycle that 
is proportional to the amount of PCR product. The cycle that the PCR product is first detected 
(Ct value) can be determined using step one Real-time PCR system. For this procedure cells 
were co cultured with different co culture techniques used and RNA was isolated. RNA was 
converted to cDNA and cDNA was amplified and measured expression of mRNA was 
quantified (122). 
 
2.11.1 Cell stimulation and culturing 
Conditioned medium from 66cl4 and 67NR 
RAW 264.7 cells were counted using Z1 Beckman cell and particle counter. Appropriate 
number of cells were seeded in a 6cm dishes or a six-well plate (9.5 cm2). Cells were placed in 
an incubator for approximately 4 hour. Attached cells were treated by desired compound (IFN-
γ and LPS or IL4) or conditioned medium of 66cl4 and 67NR with needed concentration at 
relevant time points. Appropriate amount of 66cl4 and 67NR cells were seeded as untreated 
control. After incubation for 1-2 days medium was removed and cells were harvested. 
RNAprotect cell Reagent was added to the six-well plates (500µl/well) and to 6cm dishes (1000 
µl). Detached cells were transferred to RNase-free tubes and stored at 4oC. 
  
Cultivation in transwells 
Appropriate medium was pipetted to both lower and inside compartment of the six-well plate 
transwells. Incubation for 1-2 hours was followed by medium removement. Desired number of 
RAW 264.7 cells was seeded in lower part of wells while 67NR and 66cl4 cells were seeded in 
the upper wells. Cells were incubated for 2-3 days. Medium was then removed from both lower 
and upper compartments and cells were harvested using 500µl RNAprotect Cell Reagent. 
Detached cells were transferred to RNase-free tubes and stored at 4oC. 
 
2.11.2 RNA isolation  
RNA was isolated based on Qiagen RNAprotect Cell Reagent Handbook protocol 2010 (123). 
Cells were disrupted by using RLT Plus buffer supplemented in the kit. RLT buffer was 
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prepared by adding 10µl β-mercaptoethanol (β-ME) per 1ml RLT Plus buffer. β-ME can help 
to avoid RNA degradation during RNA purification while RLT buffer lysis the membrane. Cells 
were separated from the buffer using RNeasy spin column and subsequent centrifugation. RW1 
buffer was used for washing the samples. Centrifuged column membrane was washed with RPE 
Buffer diluted in ethanol according to the manufacturer. Residual ethanol interferes with 
downstream reactions; therefore, it should be removed completely.  
 
2.11.3 Concentration measurement 
Optical density (OD) was measured using NanoDrop Spectrophotometer which is capable of 
measuring nucleic acid concentration in the higher concentrated samples than standard cuvette 
spectrophotometer at 260-280 and 260-230 nm. Based on Thermo Fisher Scientific protocol 
1µl of sample was pipetted onto the end of fiber optic cable on the instrument and concentration 
was measured using ND-1000 software (124). Instrument calculates RNA purity and sample 
concentration based on Beer’s Law (ng/µl) using 220/280 and 260/230 nm. OD ratios of 
samples at 260/280 nm should be 2.0 or more to be accepted as a pure RNA and 1.8-2-2 for 
260/230 nm. This ratio is trustable and this RNA is not contaminated. Lower ratio can be due 
to the protein or other contamination. OD of samples used in this project were more than 2. 
Samples were stored at -80oC. 
 
2.11.4 cDNA synthesize and RT-qPCR 
RNA samples were diluted in RNase-free water to a concentration of 250ng/µl to a total volume 
of 5µl. cDNA was synthesized using Qiagen QuantiTect Reverse Transcription Kit according 
to the manual (125). Genomic DNA elimination reaction master mix was prepared by mixing 
appropriate volumes of gDNA Wipeout buffer to template RNA and RNase-free water based 
on Qiagen protocol (Table2.10).Master mix was incubated 2minutes at 42 degree using thermal 
cycler. No-script reverse transcriptase and no-RNA template controls were included to ensure 
that all genomic DNA (gDNA) is removed. No-RNA template contains 2µl one of RNase-free 
water and no-script reverse transcriptase sample contains 2µl of one of the samples. 
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Table 2.10: DNA elimination reaction mix components 
Component Volume/reaction 
gDNA Wipeout Buffer, 7x 2µL 
Template RNA (250ng) 2µL 
RNase-free water 10µL 
Total volume 14µL 
 
Adequate volume of reverse-transcription master mix was prepared (Table 2.11). Reverse-
transcription master mix (6µl/well) was added to the respective template RNA (14µl/well). 
Incubation of samples for 15minutes at 42oC was followed by 3minutes incubation at 95oC 
using thermal cycler in order to inactivate Quantiscript Reverse Transcriptase. Produced cDNA 
was stored at -20°C. 
 
Table2.11. Reverse-transcription master mix components   
Components Volume (1x)µl 
Quantiscript Reverse Transcriptase 1µl 
Quantiscript RT Buffer (5x) 4µl 
RT Primer Mix  1µl 
Total volume 6µl 
 
QuantiTect Primer Assays and QuantiTect SYBR green PCR kit from Qiagen were used (Table 
2.12). Samples were diluted 1:5 using dH2O to get 10ng total cDNA concentration. Diluted 
samples were mixed and 5ng/µl or 25ng/µl of the respective cDNA was loaded (volume of the 
cDNA added should not exceed 10% of the final PCR volume). Reaction master mix was 
prepared (Table2.13). Mixed reaction master mix was dispensed into PCR plates (23µl/well) 
and respective cDNA was added. PCR plate was centrifuged for 2minutes at 1500 rpm before 
RT-PCR program running based on Qiagen protocol (Table2.14). Melting curve was set on 
65°C for 1 minute to 95 °C for 1 minute. 
 
Table 2.12: RT-qPCR QuantiTect Primer Assays 
Quantitect Primer Assay Manufacture 
NOS-2 Qiagen, Netherland (#QT00100275) 
CD163 Qiagen, Netherland (#QT00123074) 
Li Qiagen, Netherland (#QT00163646) 
Arg1 Qiagen, Netherland (#QT00134288) 
Hmbs Qiagen, Netherland (#QT00494130) 
Hprt Qiagen, Netherland (#QT00166768) 
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Table2.13: Reaction mix components 
Component Volume per 
reaction for 
5ng/µl 
Volume per 
reaction for 
25ng/µl 
2x QuantiTect SYBR Green PCR master mix 12,5 µl 12,5 µl 
10x QuantiTect Primer Assay 2,5 µl 2,5 µl 
RNase free water 8µl - 
Cdna 2 10 
Total volume 25 µl  25 µl  
 
Table2.14: Quantitative RT-PCR program on step one real time system 
PCR initial activation step 15 minutes 95°C Taq DNA polymerase activation 
Denaturation 15 seconds 94°C   
Annealing 30 seconds 55°C   
Extension 30 seconds 77°C Data collection 
Number of cycles 
 
35-40   
Depends on amounts of target cDNA 
and abundance of the target 
 
2.11.5 Statistical analysis (relative quantification) 
Ratio of target gene was determined using relative quantification (fold difference). Therefore, 
samples fold differences was calculated using an untreated sample as calibrator and an 
endogenous reference gene (housekeeping gene) as normalizer. Primers efficiency was 
calculated in the group and was included in the data analysis based on Pfaffl method described 
by manufacture. Fold induction and standard deviation was calculated using excel. Significancy 
of the obtained results were analyzed using t-test’s statistical significance in Prism 6 
(GraphPad).  
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2.12 TaqMan SNP genotyping  
TaqMan SNP genotyping assay is known for its sensitivity and ease of use and is widely used 
for detection of polymorphisms within different organisms. The prominent difference between 
this assay and other PCR methods is the utilization of sequence specific oligonucleotide 
fragments called “GMB Probes”. The opposite extremities of the probes are bind to a quencher 
molecule and a reporter molecule. TaqMan primers hybridize to the origin uphill a SNP while 
GMB probes are complementary to the sequence containing the SNP of interest. Florescent 
signal production because of the reporter/quencher cleavage leads to the detection of SNPs 
(Figure2.3) (126). In this project TaqMan SNP genotyping was used in order to investigate 
heterogeneity of 66cl4 and 67NR primary tumors and calculating percentage of non-tumor cells 
within each tumor. 
  
 
Figure2.3: TaqMan SNP Genotyping principle. TaqMan primers and probes are able to hybridize to the targeted 
SNP site. In this reaction primers are complementary to the DNA sequence and will extend due to the 5 ́ nuclease 
activity of AmpliTaq Gold DNA Polymerase. Probes are bind to a reporter and a quencher. Their cleavage due to 
the PCR amplification produces a florescent signal (126). In this assay one of probes detect wild type allele and 
the other one detect mutated allele 
 
2.12.1 Experiment designing 
BALB/cfC3H blood, 66cl4 cancer cell line, 67NR cancer cell line, 66cl4primary tumor and 
67NR primary tumor have already been exome sequenced in Bjørkøy group. The genetic 
variation of these samples and the created list of genetic variations has been checked and 
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assessed. Exome sequencing data revealed six SNPs that are homozygous in both 66cl4 and 
67NR but are not present in BALB/cfC3H blood. Primers and probes were ordered and 
designed according to the Applied Biosystems handbook (127). Homozygous mutations 
identical in both 66cl4 and 67NR cancer cell lines that does not exist in BALB/cfC3H mouse 
were identified. NCBI on line database (BLAST) was used to identify the most unique 
sequences. Sequences was sent to Applied Biosystems company and they  investigated flanking 
sequences around these mutations for primer designing. Data regarding sequence of the 
chromosome can be seen in the appendix II. 
 
2.12.2 DNA extraction  
DNA was extracted and purified from BALB/cfC3H mouse blood, Raw 264.7 cells, 66cl4 and 
67NR primary tumors and cell lines based on Qiagen Genomic DNA handbook 2012 (128). 
DNA concentration was measured using NanoDrop based on Thermo Fisher Scientific 
protocol. Instrument calculates DNA concentration (ng/µl) using absorbance ratio at 220/280 
and 260/230 nm. OD ratios of samples at 260/280 nm should be 1.8 or more and 1.8-2-2 for 
260/230 nm. DNA samples were stored at -80oC (see 2.11.3). 
 
DNA extraction from cultured cells and blood 
DNA from 66cl4, 67NR and RAW264.7 cells and BALB/cfC3H mouse blood lymphocytes 
was extracted. Cells were washed with PBS, detached from the flask using PBS-0.02% 
EDTA/trypsin and resuspended in respective medium. Cells were washed twice with PBS and 
centrifuged 5 minutes at 1500 rpm before, after and in between washings. Cell pallet was 
dissolved in 500µl PBS.  
DNA from all samples was purified by loading samples in Genomic-tip 20/G. The tips were 
washed with buffer QBT before loading and buffer QC after loading the samples. Samples go 
through the Genomic-tip by gravity flow. Genomic DNA was eluted using buffer QF and 
participated by adding isopropanol. Samples were mixed and centrifuged immediately at 5000 
g for at least 15 minutes at 4oC. DNA pellet washing with cold 70% ethanol was followed by 
Vortexing and centrifugation at 5000 g for 10 minutes at 4oC. Pellet was air dried and 
resuspended in 100µl of 10mM Tris-HCl (pH 8.5). 
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DNA extraction from primary tumor samples 
DNA was extracted from 20 mg of 66cl4 and 67NR primary tumor tissue using G2, QC, and 
QF buffers that are supplemented in the kit. Tissue samples were homogenized adding bulck 
beads and QIAGEN Proteinase K solution. After 2 hours incubation at 50°C clear lysate was 
loaded in QIAGEN Genomic-tip 20/G which was equilibrated with QBT buffer. The procedures 
that follows are identical to that exposed in the previous paragraph. 
 
2.12.3 TaqMan SNP genotyping assay 
For standard curve assessment, DNA of 66cl4 and RAW264.7 macrophage cell lines were 
mixed with different percentages (Table3.2). Then these samples were genotyped. In other 
experiments DNA samples were diluted in dH2O to a concentration of 1ng/µl to a total volume 
of 100µl. Reaction master mix was prepared (Table2.15) based on Applied Biosystems 
handbook using TaqMan genotyping master mix and custom designed probes and primer 
assays. Reaction master mix was dispensed into PCR plates (15µl) and DNA was added (10µl). 
TaqMan genotyping PCR program was set up on step one real time system using Step one 
software version 2.3 (Table2.16).  
 
Table2.15: Reaction master mix components 
Reaction component Volume/well (µl) 
TaqMan genotyping master mix (2x) 12,5 
40x Assay Mix 0,625 
dH2O 1,875 
Total Volume 15 
 
Table2.16: TaqMan genotyping PCR program on step one real time system 
Pre PCR(Holding stage) 30 seconds 60°C Data collection 
Denaturation 10 minutes 95°C  
Annealing 15 seconds 92°C  
Extension 1 minutes 60°C  
Number of cycles 40    
Post read(Holding stage) 30 seconds 60°C Data collection 
 
2.12.4 Statistical analysis 
Percentage of tumor and non-tumor cells was estimated by assessing allele 1 and 2 frequency. 
This experiment was designed based on 66cl4 and 67NR (mutated allele) and BALB/cfC3H 
blood (wild type allele). Analysis demonstrated that RAW264.7 macrophages have the wild 
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type allele. In addition, little amounts of DNA from BALB/cfC3H blood was available. 
Therefore, for creating standard curve, DNA of RAW264.7 cells was used instead of 
BALB/cfC3H blood. For creating standard curve, DNA of 66cl4 and RAW264.7 were mixed 
with different percentages. 2'-chloro-7'-phenyl-1,4-dichloro-6-carboxyfluorescein (VIC)-
labeled probes detected wild type alleles (allele1), and 6-carboxyfluorescein (FAM)-labeled 
probes detected the mutated alleles (allele2). Allele1 and allele 2 ΔRn values were extracted 
from step one software. Rn is the fluorescence of the reporter dye divided by the fluorescence 
of a passive reference dye (ROX) while ∆Rn is Rn of post-PCR read minus Rn of pre-PCR 
read. ΔRn of samples for allele 1 was relatively calculated using 66cl4 allele1 ΔRn as calibrator. 
ΔRn of samples for allele 2 was relatively calculated using RAW264.7 allele 2 ΔRn as 
calibrator. For example: 
 
1) 𝑅𝑒𝑙𝑎𝑡𝑖𝑣𝑒 𝑎𝑙𝑙𝑒𝑙𝑒 1 ∆𝑅𝑛 𝑓𝑜𝑟 100%66𝑐𝑙4 = 100% 66𝑐𝑙4 𝑎𝑙𝑙𝑒𝑙𝑒 1 ∆𝑅𝑛 −
 100% 66𝑐𝑙4 𝑎𝑙𝑙𝑒𝑙𝑒 1 ∆𝑅𝑛 
 
2)  𝑅𝑒𝑙𝑎𝑡𝑖𝑣𝑒 𝑎𝑙𝑙𝑒𝑙𝑒 1 ∆𝑅𝑛 𝑓𝑜𝑟 90%66𝑐𝑙4 + 10%𝑅𝐴𝑊264.7 = 90%66𝑐𝑙4 +
10%𝑅𝐴𝑊264.7 𝑎𝑙𝑙𝑒𝑙𝑒 1 ∆𝑅𝑛 −  100%66𝑐𝑙4 𝑎𝑙𝑙𝑒𝑙𝑒 1 ∆𝑅𝑛                                         
 
Average percentage of tumor cells was estimated based on both allele 1 and allele 2 (Figure2.4). 
For example:  
 
1) 𝑃𝑒𝑟𝑐𝑒𝑛𝑡𝑎𝑔𝑒 𝑜𝑓 𝑅𝐴𝑊264.7 𝑐𝑒𝑙𝑙𝑠 𝑖𝑛 𝑡ℎ𝑒 100%66𝑐𝑙4 𝑏𝑎𝑠𝑒𝑑 𝑜𝑛 𝑎𝑙𝑙𝑒𝑙𝑒1
=
100%66𝑐𝑙4 𝑟𝑒𝑙𝑎𝑡𝑖𝑣𝑒 𝑎𝑙𝑙𝑒𝑙𝑒1∆𝑅𝑛
100% 𝑅𝐴𝑊264.7 𝑟𝑒𝑙𝑎𝑡𝑖𝑣𝑒 𝑎𝑙𝑙𝑒𝑙𝑒1 ∆𝑅𝑛
 × 100 = 0                                           
 
2) 𝑃𝑒𝑟𝑐𝑒𝑛𝑡𝑎𝑔𝑒 𝑜𝑓 𝑅𝐴𝑊264.7 𝑐𝑒𝑙𝑙𝑠 𝑖𝑛 𝑡ℎ𝑒 90%66𝑐𝑙4 + 10%𝑅𝐴𝑊264.7 𝑏𝑎𝑠𝑒𝑑 𝑜𝑛 𝑎𝑙𝑙𝑒𝑙𝑒1
=
90 %66𝑐𝑙4 + 10% 𝑅𝐴𝑊264.7 𝑟𝑒𝑙𝑎𝑡𝑖𝑣𝑒 𝑎𝑙𝑙𝑒𝑙𝑒1∆𝑅𝑛
100% 𝑅𝐴𝑊264.7 𝑟𝑒𝑙𝑎𝑡𝑖𝑣𝑒 𝑎𝑙𝑙𝑒𝑙𝑒1 ∆𝑅𝑛
 × 100 
 
Then percentage of RAW264.7 cells in the samples was calculated based on allele 1 and 
afterwards percentage of tumor cells in each sample was calculated based on percentage of 
RAW264.7 macrophages (Percentage of tumor cells= 100 - percentage of RAW264.7).  
R-squared value (R2) for the standard curve was calculated using excel file. R2 value varies 
between o and 1 and represents how close the data are to the fitted regression line (R2= 
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Explained variation / Total variation). The closer the R-squared is to 1 the better the model fits 
the data.  
In next experiments DNA samples from 66cl4 cultured cells, 67NR cultured cells, 
BALB/cfC3H mouse blood, 66cl4 and 67NR primary tumors were genotyped. Based on results 
from experiment 1 (standard curve), frequency of alleles in these experiments was calculated 
using allele 1. As mentioned, ΔRn values of samples was used for relative calculation of tumor 
cells in tumor samples. Standard deviation (SD) was calculated using excel. 
 
 
 
Figure 2.4: Average percentage of tumor cells based on allele 1 and allele 2  
For statistical analysis, percentage of tumor cells were calculated based on both allele 1 and allele2. First 
percentage of 66cl4 cells in the samples was calculated based on allele 2 (red). Then percentage of RAW264.7 
cells in the samples was calculated based on allele 1 (blue) and afterwards percentage of tumor cells in each sample 
was calculated based on percentage of RAW264.7 macrophages (Illustrated by author).
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3. Results 
3.1 The more heterogeneous appearance of 66cl4 primary tumors is due 
to higher numbers of infiltrating cells 
Tumors are unique regarding microenvironment (22). Microenvironment composition can 
affect primary cancer growth, invasion and metastasis (21). This study was focused on the 
differences in cellular constitution and presence of macrophages in primary tumors of the 
mammary carcinoma cell lines 66cl4 and 67NR. Presence of more infiltrating cells, 
macrophages in particular, might contribute to more aggressive growth of 66cl4 primary tumor.  
Therefore, the first step was to determine if other cellular subpopulations exist in the primary 
tumors of 66cl4 and 67NR other than tumor cells. Comparing different status of infiltrated cell 
in 66cl4 (metastatic) to 67NR (non-metastatic) can give information about role of different 
infiltrated cells within primary tumors.   
 
3.1.1 Non-tumor cells can be present at primary tumors of 66cl4 and 67NR  
Previously, cultured cells, primary tumors of 66cl4 and 67NR as well as 66cl4 metastasis have 
been RNA sequenced in the Bjørkøy group. Transcriptome data represents information 
regarding cell types that can present in the primary tumors. Literature suggests different genes 
and proteins as cell specific markers. Markers of different cells that can be present in the tumors 
were chosen and summarized in table I (see appendix). Assessing both transcriptome data and 
literature can be used to indicate the presence of other cell types than tumor cells by comparing 
specific genes in the cells and tumors. Differences in mRNA expression level of stromal and 
immune cell markers in cell lines and primary tumors were compared (Table 3.1). Low mRNA 
expression in the breast cancer cells and higher expression in the primary tumors represents 
possible infiltration of the related cell type in the primary tumor. For instance, Cd68 has been 
used as a macrophage marker in several studies. Higher expression of Cd68 in primary tumor 
samples than cell lines suggests possible infiltration of macrophage within the primary tumors. 
It can also be used as a suitable marker for comparing macrophage infiltration in this model. 
Emr1- another macrophage marker- is not expressed in both cell lines and is similarly 
upregulated in both primary tumors.  
Arginase1 (ARG1) is a known marker for M2 macrophages. Analyzing transcriptome data 
reveals low expression of this marker in breast cancer cells and 67NR primary tumor and higher 
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expression mRNA level of Arg1 in 66cl4 primary tumors. Cd74 is another macrophage marker 
that is highly upregulated in both primary tumors than cancer cells. This result can be due to 
the higher infiltration of M2 macrophages in 66cl4 primary tumor than 67NR. This is supported 
by assessment of other macrophage marker candidates. However, probably there are more 
macrophage markers that can be analyzed in transcriptome data.  
Vimentin (Vim) - a well-known marker for fibroblasts- was expressed high in both cell lines 
but only expressed in one 66cl4 primary tumor. Due to this difference, further investigation 
regarding role of vim in primary tumors can be interesting. However, vimentin is highly 
expressed in the cell cultures of pure 66cl4 and 67NR and cannot be used as an indicator of 
fibroblast in this model. 
Generally, transcriptome data analysis demonstrates higher macrophage marker related mRNA 
expression in the primary tumor of 66cl4 and 67NR than tumor cells. It can be due to the 
infiltration of macrophages within primary tumors. In addition, analysis demonstrated similar 
expression of M1 macrophage markers in both 66cl4 and 67NR primary tumors. However, 
estimating number of infiltrated cells needs further investigation by other methods. 
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Table 3.1: Transcriptome Data Analysis. Markers and mRNA expression level of stromal cells in the tumor 
microenvironment 
Cell66cl4_V: Average expression value of the replicates from Cell line 66cl4. Cell67NR_V: Average expression 
value of the replicates from Cell line 67NR. Vitro_pvalue: Adjusted p-value from t-test on the comparison of 
expression values of the replicates of Cell66cl4_V and Cell67NR_V. Primary66cl4_V: Average expression value 
of the primary tumors from 66cl4. Primary67NR_V: Average expression value of the primary tumors from 67NR. 
Vivo_pvalue: Adjusted p-value from t-test of the comparison of primary tumors from 66cl4 and 67NR 
 
Cell type Gene 66cl4 
Cell line 
_V 
67NR 
Cell line 
_V 
Vitro 
_p value 
 
66cl4 
Primary 
tumor_
V 
67NR 
Primary 
tumor_
V 
Vivo 
_p value 
Macrophages 
general 
marker 
Cd68 1,36905 5,08001 0,0001156 182,48 96,8061 0,0001985 
Emr1 0,0198353 0,0159229 1 60,9174 67,5694 0,350149 
M1 
Macrophages 
Fcgr1 0,0274622 0,0474556 1 35,1767 38,2861 0,46828 
Nos2 0,101048 0,001711 1 1,5577 2,04159 0,178111 
Cd40 0,0313455 0,01 1 4,52739 4,34538 0,868842 
Cd80 0,357589 0,913047 0,0001156 3,55156 3,61519 0,947027 
Cd74 0,746012 0,44891 0,0193102 435,416 898,108 0,0001985 
M2 
Macrophages 
Cd163 0,0195665 0,0029088 1 32,8626 7,59919 0,0001985 
Arg1 0,0084714
3 
0,00906541 1 114,616 0,191906 0,0001985 
Mrc1 0,125848 0,096672 1 202,967 113,804 0,0001985 
B cell 
 
Cd300lg 0,01 0,01 1 5,17632 6,78337 0,100145 
Cd300a 0,0173552 0,0791101 1 4,78531 7,32302 0,0003761 
T cell 
general 
marker 
 
Cd3e 0,0091694 0,01 1 1,23928 4,64167 0,0001985 
Cd3d 0,0239321 0,01 1 1,7272 4,32501 0,0018929 
Cd3g 0,0200508 0,00717778 1 4,3106 13,5648 0,0001985 
Helper T cell Cd4 0,0037259 0,01 1 1,51006 7,20981 0,0001985 
Cytotoxic T 
cell 
Cd8a 0,01 0,01 1 0,700704 4,56732 0,0001985 
Fibroblast Vim 1456,38 2921,7 0,0001156 2009,47 0,01 1 
NK cells Ncr1 0,0043006 0,0092422 1 4,87394 13,4194 0,0001985 
Dendritic cell Cd83 0,0057225 0,00904042 1 20,9866 15,5939 0,0107666 
Il3ra 0,01 0,01 1 3,09863 2,46223 0,386578 
Endothelial 
Cell 
Cd34 77,682 86,402 0,258236 69,9401 127,617 0,0001985 
Pecam1 0,0269223 0,0614277 1 34,3667 32,9393 0,735822 
Vcam1 0,709771 0,8733 0,159097 8,665 24,6174 0,0001985 
Cdh5 0,0390046 0,119393 1 27,916 26,3239 0,625893 
Monocytes Csf1r 0,052124 0,08567 1 164,309 120,572 0,005756 
Neutrophil Itgam 0,018483 0,02412 1 85,6426 43,5374 0,0001985 
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3.1.2 66cl4 and 67NR primary tumor heterogeneity is due to the presence of non-
tumor cells in tumor stroma 
Transcriptome data analysis suggested the presence of non-tumor cells in the 66cl4 and 67NR 
primary tumors. The presence of non-tumor cells can be determined by analyzing mutated and 
wild type allele. DNA isolated from BALB/cfC3H mouse blood, 66cl4 and 67NR breast cancer 
cells was previously exome sequenced. TaqMan genotyping assay was performed in order to 
investigate existence of non-tumor cells in the primary tumor samples. DNA sequence of 66cl4 
and 67NR cancer cells were investigated in order to identify common genetic variant specially 
for tumor cells. Primers and probes were designed based on the identical mutations in 66cl4 
and 67NR cancer cells that does not exist in BALB/cfC3H mouse. 2'-chloro-7'-phenyl-1,4-
dichloro-6-carboxyfluorescein (VIC)-labeled probes detected wild type alleles (allele1), and 6-
carboxyfluorescein (FAM)-labeled probes detected the mutated alleles (allele2). It was 
speculated that number of tumor and non-tumor cells can be estimated by calculating frequency 
of allele 2 and allele 1, respectively. For the first step, accuracy and sensitivity of this technique 
and the designed primers and probes should be analyzed. RAW264.7 cells were used is this 
experiment as sample that does not possess the mutant allele. The standard curve was plotted 
by mixing DNA of 66cl4 with increasing amount of RAW264.7 DNA ranging from 10% up to 
90%. Then these samples were genotyped. As the allelic discrimination plot indicates, pure 
66cl4 cultured cell DNA exhibits more homozygosity for allele 2 (A/A, FAM) and pure 
RAW264.7 macrophage DNA demonstrate signal for allele1 (G/G, VIC) (Figure 3.1). With 
increasing amount of RAW264.7 DNA, the signal for allele 2 decreased and at the same time 
the signal for allele 1 increased. Allele 1 ΔRn was plotted against allele 2 ΔRn. A linear 
regression with the high R-squared (R2) value was observe. The closer the R2 is to 1 the better 
the model fits the data. In this experiment R2 value (0.9783) demonstrates closeness of the data 
to the fitted regression line (Figure 3.1). 
As it has been described in material and method section (section 2.12.4), for calculating 
frequency of allele 1, ΔRn of each sample was quantified relatively based on 66cl4 ΔRn. For 
calculating frequency of allele 2, ΔRn of each sample was quantified relatively based on 
RAW264.7 ΔRn. Average percentage of tumor cells was estimated based on both allele 1 and 
allele 2 (Table3.2). The calculated percentage of the tumor cells was compared with the pipetted 
sample. Results from allele 1 demonstrated that the calculated percentages are closer to the 
actual values and a linear decrease in number of tumor cells was observed. As it can be seen in 
table 3.2 number of tumor cells in the sample containing 90% 66cl4 is close to sample that 
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contains 15% less of 66cl4 DNA. In contrary, no linear range in average number of tumor and 
non-tumor cells by decreasing concentration of 66cl4 DNA in samples based on allele 2 was 
observed. Based on these results, allele 1 seems to be more suitable for calculating percentage 
of nun-tumor cells. 
 
Figure 3.1: Allelic discrimination standard plot of RAW264.7 cells and 66cl4 cancer cells 
Allelic discrimination plot demonstrates genotyping results from TaqMan SNP genotyping assays for eight 
different samples. 66cl4 and RAW264.7 cells were genotyped by analyzing mixture of 66cl4 cultured cells and 
RAW264.7 cells. X and Y-axis demonstrates Vic and FAM signal fluorescence values, respectively, which are 
used for the clustering of the samples. Therefore, 66cl4 cells that exhibits FAM signal is homozygous for allele 2 
and RAW264.7 sample (VIC signal) is homozygous allele 1. Samples that are mixture of two different DNA were 
elevated both FAM and VIC signal. It demonstrates exhibition of both alleles in different percentage. 
 
 
Table 3.2: Percentage of tumor cell average based on allele 1 and allele 2 
Sample 
 
 
Number of tumor 
cells based on 
allele1 
Number of tumor 
cells based on 
allele2 
100%66cl4  100 100 
90%66cl4 +10% RAW264.7 88,71167285 76,31594178 
75%66cl4 +25% RAW264.7 75,92801956 78,01868434 
50%66cl4 +50% RAW264.7 55,8744944 59,61132131 
25%66cl4 +75% RAW264.7 23,8833765 30,81832513 
10%66cl4 +90% RAW264.7 10,0633295 15,4231007 
100% RAW264.7 0 0 
 
Data from the first experiment demonstrated that allele frequency and subsequently number of 
tumor and nun tumor cells can be calculated based on allele1 using ΔRn of each allele in the 
sample. In order to investigate cellular heterogeneity of 66cl4 and 67NR primary tumors 
TaqMan SNP sequencing assays were performed. For this experiment, the DNA samples from 
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66cl4 cultured cells, 67NR cultured cells, BALB/cfC3H mouse blood, 66cl4 and 67NR primary 
tumor were genotyped. Allelic discrimination plots from two different experiments demonstrate 
the intensity allele 2 (mutated) signal in 66cl4/67NR cultured cells and intensity of allele 1 
(wild type) signal in BALB/cfC3H mouse blood (Figure 3.3). Results from experiment A 
demonstrated a linear range between samples using chromosome 1 primer assay. However, 
tumor samples in experiment B demonstrate deviation from the regression line on allelic 
discrimination plot. As it has been demonstrated, deviation of allele 2 was observed in the 
standard curve. This deviation might be due to the nonspecific binding of the probe detecting 
the mutated allele. Samples ΔRn was used for estimating number of tumor and non-tumor cells 
in the primary tumors. Results from these two experiments can suggests that ΔRn values of 
samples can be used for relative calculation of tumor cell/normal cell percentage in tumor 
sample based on allele1. Statistical analysis suggests that almost 40% of 66cl4 primary tumors 
and 30% of 67NR primary tumors are non-tumors cells.  
 
Figure 3.2: Allelic discrimination plot chromosome 1 primer assay  
A) and B) represent allelic discrimination plot of two different experiment based on chromosome 1 probe and 
primer assay. This blot demonstrate ΔRn of genotypes G/G (willed type, allele 1), G/A and A/A (mutated, allele 
2). VIC represents wild type on x-axis and FAM demonstrates mutated allele on y –axis. 
Results 
 
51 
3.1.3 66cl4 primary tumor sections are more heterogeneous than 67NR 
In order to assess heterogeneity of 66cl4 and 67NR primary tumors and identify presence of 
infiltrated cells, pre-stained H&E sections were investigated. Formalin-fixed paraffin 
embedded (FFPE) sections of 66cl4 and 67NR primary tumors were stained with hematoxylin 
and eosin dyes. 66cl4 primary tumor sections seem more heterogeneous that 67NR (Figure 3.3). 
In 66cl4 primary tumor sections, a mixture of tumor cells and non-tumor cells were observed 
(Figure3.3A). Some cells were tagged as potential macrophages (thick arrows) with a foamy 
cytoplasm and a rounded nucleus. Lymphocytes (thin arrows) could be observed with round 
nucleus and smaller portion of cytoplasm compared to macrophages. No structure that could 
represent a fibroblast or a dendritic cell was identified. Nevertheless, these cell types cannot be 
certainly defined by H&E staining and a more precise method such as immune staining is 
needed. 
In contrary, in 67NR primary tumor sections cells are more compact and most of the cells seems 
similar (Figure 3.3B). 67NR tumor sections looks less heterogeneous than 66cl4. This is in 
contrary with genotyping results that suggests heterogeneity in both primary tumors.  
 
 
Figure 3.3: H&E stained sections of 66cl4 are more heterogeneous than 67NR 
Hematoxylin is a basic dye and stains nucleus purple while eosin is an acidic dye that stains basic cytoplasm pink 
with eosin. Images were obtained using EVOS FL Auto Cell microscope. A) 66cl4 primary tumor sections seem 
heterogeneous(×10). Macrophages (thick arrows) with foamy cytoplasm and lymphocytes (thin arrows) with 
smaller cytoplasm and big round nucleus can be observed in the 66cl4 tumor section in focus (×40). B) 67NR 
tumor sections do not seem heterogeneous. No specific cell structure can be distinguished in the 67NR tumors 
(×10 and ×40). Right side bars in the upper images are 400 µm and in down images are 60µm. 
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3.2 66cl4 tumor heterogeneity can be due to the presence of polarized 
macrophages, M2 macrophage in particular 
Results from studies in section 3.1 demonstrated higher number of non-tumor cells within 66cl4 
primary tumors than 67NR. Identification of tumor microenvironment subpopulation is 
necessary and leads to better understanding of their function in tumor progression. Accumulated 
evidence demonstrates that macrophage infiltration promote metastasis of breast tumor and 
correlated with aggressive breast tumor behavior (96-98). Therefore, presence and polarization 
of macrophages in the primary tumors of 66cl4 and 67NR were investigated. 
 
3.2.1 There is no correlation between expression of Cd68, Nos2 and Arg1 and 
human breast cancer patients survival  
Based on literature study and by assessing transcriptome data, one M1, one M2 and a general 
macrophage marker were chosen for further analysis. NOS2, ARG1 and CD68 have been used 
in several studies as M1, M2 and general macrophage marker, respectively. In order to study 
correlation between mRNA expression of these genes and patient survival, Breast mark online 
database was used (129). Median mRNA expression of each gene in tumor grade 3 (metastatic) 
in general and in basal-like tumors related to disease free survival (DFS) was analyzed. In this 
algorithm, Pam50 category that utilizes the genes from Parker et al., 2009 to subtype the breast 
cancer samples was studied (130). There is no correlation between survival rate in breast cancer 
patients and low or high expression of these three genes (Figure3.4). However, these markers 
were used in this study as macrophage markers that can be used in different methods such as 
immunostaining and immunoblotting.  
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Figure 3.4: Correlation between mRNA expression of Cd68, Nos2 and Arg1 and the survival endpoint of 
the breast cancer as whole and basal like  
In this graph, cut-off is used to dichotomize the data, allowing stratification into high and low groups within each 
of the individual datasets. The High Expression group in each plot (blue) have expression greater than the cut-off  
the Low Expression group (red) have expression less than the cut-off, in each of the individual datasets and this is 
then combined to perform a global pooled survival analysis. N is the number of samples used in this comparison. 
The Hazard ratio is generated using Cox regression and a log rank test is used to assign significance to the Hazard 
ratio. The Hazard ratio always relates to increased expression of the marker. A) N= 544, Number of events=201, 
Hazard ration=0.9454 (0.7151 - 1.25). B) N= 154, Number of events=49, Hazard ration=1.039 (0.5919 - 1.823). 
C) N= 544, Number of events=201, Hazard ration=0.9044 (0.6537 - 1.251) D) N= 154, Number of events=49, 
Hazard ration=0.9529 (0.4867 - 1.866) E) N= 544, Number of events=201, Hazard ration=0.8545 (0.6324 - 1.154). 
F) N= 154, Number of events=49, Hazard ration=0.5965 (0.3044 - 1.169). 
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3.2.2 Different protein expression level of ARG1 were observed in 66cl4 and 
67NR primary tumors and cell line by immunoblotting 
Macrophage infiltration within primary tumor environment can correlated with metastatic 
potential of the tumor. M2 macrophages can increase tumor metastasis (73). Western blot 
analysis was performed in order to investigate infiltration and polarization of macrophages in 
metastatic 66cl4 and non-metastatic 67NR primary tumors. Therefore, protein expression of 
ARG1 and NOS2 in the 66cl4 and 67NR tumors was assessed. RAW264.7 cell stimulated with 
IFN-γ and LPS was used as control for NOS2 expression. NOS2 expression was not detected 
in cancer cells and primary tumors. ARG1 expression was detected in 66cl4primary tumor 
while its expression in 67NR primary tumor and both cancer cell lines could not be observed 
(Figure3.5). This difference can be assumed as macrophages polarization variant within 
primary tumors.  
 
Figure 3.5: Different level of NOS2 and ARG1 were expressed in 66cl4 and 67NR primary tumors and 
cancer cell lines  
Stimulated RAW264.7 cells with IFN-γ and LPS were used as a positive control for NOS2 expression. Membrane 
was stained for NOS2 (125 kDa), ARG1 (37 kDa) and ACTB (42 kDa) as loading control. Labelled bonds were 
detected with odyssey near infrared imager. Number above the first band represents different replicate for each 
sample. Protein expression of ARG1 can be observed in 66cl4 primary tumor lysates (black arrow). 
 
3.2.3 Macrophages could not be localized in 66cl4 primary tumor sections by 
immunostaining of ARG1 and NOS2 
Although H&E staining technique can be used for pathological prognosis, precise identification 
of specific cells needs a more accurate method. In order to localize and identify polarized 
macrophages within 66cl4 primary tumor, FFPE 66cl4 tumor sections were stained for ARG1 
and NOS2 macrophage markers and scanned with Odyssey infrared imaging system (Figure 
3.5). Negative controls were only stained with secondary antibodies (Figure3.5, 2). The same 
Results 
 
55 
regions were stained for NOS2 and ARG1 over the section (Figure3.5, 1). Therefore, localizing 
macrophages was not possible in this assay. Two different conclusions can be resulted. First, 
primary antibodies were not specific and specialized for this assay. Second, this technique is 
not sensitive enough distinguishing between macrophage subtypes. Consequently, more 
sensitive system such as confocal microscopy that can scan sections with higher resolution was 
needed.  
 
Figure 3.5: Macrophage localization in 66cl4 primary tumor sections using immunostaining by florescent 
secondary antibodies  
1) 66cl4 primary tumor sections were stained using NOS2 and ARG1 primary antibodies and florescent secondary 
antibodies. 2) Negative controls were only stained with secondary antibodies.  
Sections were scanned using Odyssey infrared imager. No clear difference was observed between stained proteins 
for NOS2 (red, 680nm) and ARG1 (green, 800nm). Single stained images for NOS2 and ARG1 are shown, together 
with merged images containing NOS2 and ARG1. The scale bar in the right corner is 1cm (one pixel on the picture 
is about one cell). 
 
3.2.4 Macrophages could not be localized in 66cl4 and 67NR primary tumor 
sections utilizing confocal microscopy 
In order to localize macrophages within 66cl4 and 67NR primary tumors, FFPE sections were 
stained for CD68 as general macrophage marker. In order to facilitate discrimination between 
tumor and non-tumor cells, GFP tagged tumor cells were injected to the BALB/cfC3H mouse. 
GFP tagged tumor cells would expected to emit green florescent and be easier distinguished 
from macrophages. Both 66cl4 (Figure3.6, A) and 67NR primary tumor (Figure3.6, B) sections 
were stained with CD68 primary antibody and secondary antibody that can be detected by 
confocal microscopy. 66cl4 and 67NR negative controls (slides number 3) that were not stained 
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with primary antibodies demonstrated nonspecific signal. No clear difference in staining 
between negative controls and the stained sections was observed. It can be due to 
autofluorescence of samples, nonspecific binding of secondary antibodies or even fail in 
tagging tumor cells with GFP. 
 
Figure 3.6: Macrophages could not be localized in 66cl4 and 67NR primary tumor sections utilizing confocal 
microscopy 
A) 66cl4 primary tumor sections B) 67NR primary tumor sections.  
All the sections were stained for CD68 (red), GFP (green) and for nuclei with DRAQ5 dye (blue). Slides 1 and 2 
were stained with both primary and secondary antibodies. Sections number 3 were only stained with secondary 
antibodies (negative control). Secondary antibodies are conjugated with alexa555 (CD68, red) and alexa488 dye 
(GFP, green). Single stained images for CD68 and GFP are shown, together with merged images containing CD68, 
GFP and nucleus staining.  The bar in the right corner is 50µm. 
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3.3 RAW264.7 cell line is not suitable for designing an in vitro model to 
study Interaction of 66cl4 and 67NR breast cancer cells and macrophages  
Metastasis is the leading cause of death in breast cancer patients. Two mouse cell lines 66cl4 
(metastatic) and 67NR (non-metastatic) primary tumors demonstrated different metastatic 
potential. TAMs are known for contribution in tumor metastasis. Based on previous result 
explained in section 1 and 2 of the result chapter, it was assumed that macrophages are present 
in the 66cl4 primary tumors. Complexity of breast tumor microenvironment is a barrier for 
studying interaction of tumor cells with normal cells. Modeling interaction of macrophages 
with 66cl4 and 67NR primary tumors can lead to more understanding about tumor progression 
and the more aggressive growth of 66cl4 tumors. First important step is finding a macrophage 
cell type that is easy to handle and can change polarization by different stimuli. Different 
macrophage cell lines can be used for this purpose. RAW264.7 is a mouse-derived cell line; 
therefore, it can be a good option for studying tumor and macrophage interaction. Chen F et al., 
2014 considered mouse RAW264.7 macrophage cell line as “M0” that can be polarized toward 
M1/M2 macrophages by different maturation methods (131). Therefore, polarization of 
RAW264.7 cells tumor cell co-cultures or after adding conditioned medium from the cancer 
cells was investigated.  
 
3.3.1 Macrophage polarization cannot be observed by immunostaining 
RAW264.7 cells treated with conditioned medium of 66cl4 and 67NR  
The first step for testing the designed in vitro model was to investigate whether culturing 
RAW264.7 macrophage cells with conditioned medium of 66cl4 and 67NR cells can change 
the macrophage polarization. RAW264.7 cells reactivity potential to extracellular stimulation, 
can introduce this cell line as a good option for future research. RAW264.7 cells were seeded 
in confocal plate in presence of 50% or 100% conditioned medium of 66cl4 and 67NR. 
Combination of IFN-γ plus LPS and IL4 were used as a positive control for M1 and M2 
polarization, respectively. Stimulated cells were stained for NOS2 and ARG1 and analysed by 
confocal microscopy (Figure3.8). ARG1 positive staining was observed in the negative control, 
therefore, results are not comparative and trustable. However, comparison between different 
stimulations implies that more likely conditioned mediums could not effect RAW264.7 cells 
polarization. It seems that RAW264.7 cells stimulation with IFN-γ and LPS could increase 
NOS2 expression compared to negative control and other stimulations. However, this result 
should be confirmed by other methods such as Western blotting.  
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Figure3.8: It is impossible to observe NOS2 and Arg1 protein expression in stimulated RAW 264.7 cells by 
confocal microscopy 
A) RAW264.7 cells were treated with 66cl4 and 67NR conditioned mediums (50% and 100%). B) RAW264.7 
cells were stimulated using IFN-γ (10ng/ml) and LPS (10ng/ml) or IL4 (10ng/ml). Negative control (-) was not 
stimulated and only stained with secondary antibodies. 
Seeded cells were stained for macrophage markers NOS2 and ARG1 and for nuclei with DRAQ5 dye (blue). 
Secondary antibodies are conjugated with alexa555 (NOS2, red) and alexa488 dye (ARG1, green). Single stained 
images for NOS2 and ARG1 are shown, together with merged images containing NOS2, ARG1 and nucleus 
staining.  The bar in the right corner is 10µm. 
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3.3.2 No difference in proteins expression level of NOS2 and ARG1 in RAW264.7 
cells treated with conditioned medium 
No confidential difference in RAW264.7 macrophage polarization using conditioned medium 
of cancer cells was observed by immunostaining. By using western blot, changes in protein 
expression level of NOS2 and ARG1 as macrophage markers using conditioned medium of 
cancer cells can be investigated. RAW264.7 cells were seeded in plates and harvested for 
immunoblotting. Lysate from 66cl4 primary tumor was used as a positive control for ARG1 
expression. Unstimulated cells were used as negative control. RAW264.7 cells stimulated with 
IFN-γ and LPS or IL4 were used as positive control for M1 and M2 polarization, respectively. 
No difference in morphology of the cells after stimulation using light microscope was observed. 
Membrane was stained for NOS2 and ARG1 antibodies. Immunoblot analysis demonstrated 
that RAW264.7 cells are responsive to IFN-γ and LPS stimulation and express NOS2 
(Figure3.9). This result can proof results from immunostaining. In addition, RAW264.7 cells 
did not express ARG1 after stimulation with IL4 with different concentrations and at different 
time-points.No difference in expression of NOS2 and ARG1 proteins in cells treated by 
conditioned medium compared to negative control was observed.  
 
 
Figure 3.9: No difference in protein expression level of NOS2 and ARG1 was observed in treated RAW264.7 
macrophages with conditioned mediums of 66cl4 and 67NR 
RAW264.7 macrophage cells were treated with 50% conditioned medium of 66cl4 or 67NR for 48 hours. Positive 
control cells were stimulated using 10ng/ml IFN-γ and LPS or 50 ng/ml IL4 at different time points (48 hours or 
24+24 hours). 66cl4 primary tumor cell lysate was loaded as a positive control of ARG1 protein expression. Un 
stimulated control is indicated by ‘-‘in the image. Membrane was stained for NOS2 (125 kDa), ARG1 (37 kDa) 
and ACTB (42 kDa) as loading control. 
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3.3.3 No mRNA expression of Nos2, Cd163 and Arg1 and no difference in 
expression of Cd74 was observed in RAW264.7 cells stimulated by conditioned 
mediums  
Western blotting could not detect polarization in RAW264.7 cells by stimulation with 
conditioned medium of 66cl4 and 67NR. This can be due to the low protein expression level 
and insensitivity of method for detecting that. Thus, expression of two M1 macrophage markers 
CD74 and iNOS and two M2 macrophage markers Cd163 and Arg1 was assessed by RT-qPCR.  
RAW264.7 cell were stimulated with conditioned medium of 66cl4 and 67NR, IFN-γ plus LPS 
and IL4. In addition, in order to increase cells interaction without direct physical contact, cells 
were cultured in trans-well. Results from this assay demonstrated no expression of Nos2, Cd163 
and Arg1in stimulated samples. Ct values for these genes were so high (more than 30-35 cycle) 
even by increasing cDNA concentration from 5ng/µl to 50ng/µl; therefore, the data obtained 
from those genes was not trustable. Nos2, Cd163 and Arg1 mRNAs were not expressed in the 
samples. Expression of Cd74 could be analyzed due to the lower Ct values (Figure3.10). IFN-
γ and LPS stimulation upregulated Cd74 expression in RAW264.7 macrophages. No significant 
upregulation of Cd74 mRNA expression was observed in RAW264.7 cells using trans-well and 
condition medium of 66cl4 and 67NR cancer cells (P˃o.o5). 
 
 
Figure3.10: No significant difference in expression level of Cd74 in stimulated RAW264.7 cells was assayed 
by quantitative real-time PCR (qPCR) 
RAW264.7 cells were stimulated by 50% conditioned medium of 66cl4 and 67NR or co-cultured in a trans-well 
dish with 66cl4 and 67NR cells. RAW264.7 cells were also stimulated with IFN-γ and LPS 10ng/ml (24hours) or 
IL4 10ng/ml (24 hours) as positive controls. Fold changes of RNA expression level of Cd74 gene in stimulated 
samples was compared to untreated using t-test’s statistical significance analysis. Standard deviation (SD) is shown 
in the figure as a bar (n=3). 
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3.4 IC-21 cell line is not suitable for designing an in vitro model in order to 
study Interaction of 66cl4 and 67NR breast cancer cells and macrophages  
As studies in section 3 of the result chapter demonstrated, RAW264.7 macrophages did not 
respond to stimulation by conditioned medium or co-culture with cancer cells. Therefore, this 
cell line is not suitable for designing an in vitro model for studying macrophage and breast 
cancer cells interplay. Thus IC-21 cell line was tested for aim of this study. IC-21 is a C57BL/6 
mouse adherent cell line was. Consequently, polarization of IC-21 macrophages in presence of 
different stimuli was assessed. 
 
3.4.1 No difference in protein expression of NOS2 and ARG1 in treated IC-21 cells 
with conditioned mediums was observed 
In order to investigate influence of different stimuli on IC-21 macrophages, these cells were 
cultured in the presence of 50% 66cl4 and 67NR conditioned mediums. Controls were untreated 
or stimulated with IFN-γ and LPS or IL4. Cells with different stimulations were monitored 
using EVOS cell imaging microscope. No significant difference in morphology of IC-21 cells 
was observed. Immunoblot analysis demonstrated an increase in NOS2 protein level by 
stimulating IC-21 cells with IFN-γ and LPS (Figure3.11), although to a lesser extent than 
RAW264.7 cell. In addition, IC-21 cells did not express ARG1 after IL4 stimulation. No 
difference in expression of NOS2 and ARG1 proteins in cells treated by conditioned medium 
was observed.  
 
Figure 3.11: No difference in protein expression of NOS2 and ARG1 in treated IC-21 cells with conditioned mediums 
was observed 
Seeded IC-21 cells were stimulated for 48hours using 50% conditioned medium of 66cl4 or 67NR. Controls were 
stimulated using 10, 20, 25 and 50ng/ml IFN-γ and LPS or 10, 20, 25 and 50 ng/ml IL4 for 24 hours. 66cl4 primary 
tumor cell lysate was loaded as a positive control of ARG1 protein expression. Unstimulated control was indicated 
by ‘-‘in the image. Membrane was stained for NOS2 (125 kDa), ARG1 (37 kDa) and ACTB (42 kDa) as loading 
control.
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4. Discussion 
The two breast cancer cell lines 66cl4 and 67NR have different metastatic potential (118, 119). 
Tumor microenvironment constitution can influence tumors characteristics (21). Genotyping 
results demonstrated that about 40% of 66cl4 and 30% of 67NR primary tumors consist of non-
tumor cells. Macrophages are important compartments of tumor microenvironment that 
contribute in breast carcinogenesis (96-98). TAMs associating tumor progression are 
predominantly M2 macrophages (132). Based on immune blot and transcriptome data analysis, 
it can be assumed that more M2 macrophages infiltrated within 66cl4 primary tumor than 
67NR. Metastasis and cancer progression is a complex phenomenon that can be depended on 
different stroma cell types. Therefore, it would be more practical to study interaction of tumor 
cells and macrophages in vitro. Two different macrophage cell lines were chosen for designing 
this model. Experimental data suggests that RAW264.7 and IC-21 macrophage cell lines are 
not ideal models for studying this interaction. 
 
4.1 66cl4 and 67NR primary tumors heterogeneity is due to infiltrated cells 
Tumor microenvironment contributes to tumor suppression or growth and metastasis(22). It is 
well evident that breast cancer cells continuously interact with infiltrated non-tumor cells 
including immune cells in the tumor microenvironment (133). It is notable that each tumors is 
unique regarding to their microenvironment (22). It is interesting to compare metastatic and 
non-metastatic tumors heterogeneity, cellular composition and different infiltrated cellular 
polarization. This information can help understanding correlation between infiltrated cells with 
metastasis. A wide range of experimental models can be used for studying different aspects of 
breast tumor carcinogenesis (112). However, based on aim of this study, it is valuable to 
investigate tumor cellular composition in a syngeneic, non-manipulated mouse model with a 
functioning immune system.  
Tumor cell composition can be characterized and distinguished by investigating specific cell 
markers expression. A number of reports suggest a variety of markers for different cell type. 
Comparing expression of these markers with the transcriptome data can help choosing the most 
suitable marker for the study. Analyzing transcriptome data of cultured cells and primary tumor 
of 66cl4 and 67NR represents valuable information regarding sum of the cells in the primary 
tumors. Low mRNA expression in the breast cancer cells and higher expression in primary 
tumors can indicate possible infiltration of different immune cells within the primary tumors. 
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Based on transcriptome data analysis, three different macrophage markers were chosen for 
further investigation. CD68, ARG1 and NOS2 are general, M2 and M1 macrophage markers, 
respectively (134). Transcriptome data analysis demonstrated higher mRNA expression of 
Cd68 and Nos2 in primary tumors than breast cancer cells. Low Arg1 mRNA expression in 
both breast cancer cells and 67NR primary tumor than 66cl4 primary tumor might be due to the 
higher infiltration of M2 macrophages in 66cl4 primary tumor than 67NR. In addition, same 
trend was observed in other macrophage marker candidates. It is notable that there might be 
other macrophage markers in the transcriptome data that can be analyzed for more precise 
calculation. 
Based on average expression of macrophage markers, it can be interpreted that macrophages 
are infiltrated to 66cl4 and 67NR primary tumors. However, it should be noted that upregulation 
of genes in primary tumors compared to cancer cells, does not necessarily correlate with cell 
infiltration. All of these markers can be upregulated in primary tumors and also be expressed 
by other cell types than what it is mentioned in some literature. For example CD68 has been 
known as a macrophage marker (47, 134). Kunz-Schughart LA et al., 2003 investigated CD68 
protein and gene expression in fibroblasts. They have claimed that CD68 is not only expressed 
in macrophage lineage but also fibroblasts isolated from normal and tumor breast tissue express 
CD68 at comparable level to macrophages (135). Therefore, further investigation regarding 
macrophage infiltration is necessary. 
It is notable that analysis of transcriptome data can give hints of type infiltrated cells but not 
number of cells since both increased number of cells and increased expression of a marker in 
few cells can influence mRNA expression level.  
For estimating number of infiltrated cells to the tumor microenvironment, SNP frequency was 
analyzed. This primer assay was designed based on identification of a homozygous point 
mutation in both 66cl4 and 67NR cancer cell lines that does not exist in BALB/cfC3H mouse. 
This novel approach tried to estimate percentage of non-tumor cells within 66cl4 and 67NR 
primary tumor by investigating frequency of mutated allele (A/A) and wild-type allele (G/G) 
in the tumor samples. Sequence detection system in the Real-Time PCR system had measured 
florescence signal before and after the amplification. Relative quantification of allele’s ΔRn 
was done in order to assess relative amount of the target nucleic acid in samples by comparing 
each samples with calibrator. Here calibrator for mutated allele is 66cl4 and for wild-type allele 
is RAW264.7 or BALB/cfC3H blood. For first test, in order to test accuracy and sensitivity of 
this method and designed primers standard curve was plotted. Result from allele 1 demonstrated 
a linear decrease in number of tumor cells by reducing percentage of 66cl4 DNA. In contrary, 
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results from allele 2 is not comparative with volume of pipetted DNA. PCR conditions might 
not be optimal and can lead to these deviations. Errors in probe designing cam cause this 
deviation as well. However, results suggested that allele 1 might be suitable for calculating 
percentage of nun-tumor cells within primary tumor samples. 
This statistical analysis was based on mathematical approaches and relative quantification that 
is common technique for RT-qPCR. Assessing results from this experiment suggests that 
sample ΔRn can be used for estimating percentage of tumor and non-tumor cells within a 
primary tumor.  
In order to estimate number of tumor and non-tumor cells within a primary tumor of 66cl4 and 
67NR, allele frequency was determined using TaqMan SNP genotyping assay. Statistical 
analysis demonstrated that almost 40% of 66cl4 primary tumors and 30% of 67NR primary 
tumors are consist of non-tumor cells. Comparing these results with results from transcriptome 
data analysis demonstrated infiltration of cells within primary tumors of 66cl4. Previous studies 
have also demonstrated infiltration of  immune cells such as lymphocytes (136) and 
macrophages (137) to breast tumor. Infiltrated immune cells play an important role in cancer 
related inflammation (33) and macrophages represent a major component of infiltrated cells 
within solid tumors (138).  
This assay can be limited by technical error. Tumor isolation can be along with isolation of the 
tissue that surrounded the tumor that can influence the results and increase number of non-
tumor cells in the sample. However, in order to increase accuracy of the study, several samples 
of 66cl4 and 67NR primary tumors were analyzed. Producer suggested post-plate read (139). 
In this experiment sample ΔRn was obtained by pre and post plate read. Plate reading during 
amplification can indicate Ct values that are used in RT-qPCR relative calculations (122). For 
future study, Ct value can be substituted with ΔRn for allele frequency calculation. In addition, 
accuracy of this technique can be examined by plotting standard curve for 67NR. BALB/cfC3H 
mouse blood can be used instead of RAW264.7 cells in order to increase precision of the 
experiment and for data comparison.  
This assay demonstrated valuable information regarding percentage of tumor and non-tumor 
cells within 66cl4 and 67NR primary tumors. However, these results do not provide any 
information about non-tumor cellular composition and its contribution in the primary tumors 
suppression or progression. Characterizing different cell types in the primary tumor allow a 
more precise interpretation of their function in breast tumor.  
In order to identify infiltrated cells within primary tumors of 66cl4 and 67NR, H&E stained 
sections were assessed. Analysis H&E stained sections demonstrated heterogeneity in 66cl4 
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primary tumor sections. In 67NR primary tumor sections, tumor cells were in close distance to 
each other and cells were seem similar. Results from genotyping assay suggested heterogeneity 
in both 66cl4 and 67NR primary tumors, however in 67NR primary tumor unique section 
pattern was observed. This result is contradictory with genotyping and transcriptome data 
results that suggest non-tumor cell infiltration within both primary tumors. H&E staining is not 
the best option for studying tissue cellular compartment but it is an initiation for further staining. 
Other techniques such as immunofluorescence staining allows us to stain for different cell type 
and distinguish easier without need to know morphology of each cell. Thus, markers that have 
been chosen based on literature and transcriptome data can possibly stain for protein of interest 
(CD68, ARG1 and NOS2) by other techniques such as immunofluorescence staining.  
 
4.2 66cl4 and 67NR tumor heterogeneity is due to the presence of 
polarized macrophages, M2 macrophages in particular 
Macrophage can constitute up to 80% of leukocyte in final stage of mouse mammary carcinoma 
(31). Previous studies demonstrated role of infiltrated TAMs in breast tumor progression (96-
98). Macrophages can be schematically sub divided to M1 and M2 macrophages (41, 52). M1 
macrophage are important players of the innate immune defense (54) while M2 macrophages 
increase tumor metastasis and immune suppression in tumor microenvironment (73). TAMs 
associating tumor progression are predominantly M2 macrophages (132).  
Based on literature study and results from the first part of the project, this study focused on 
macrophage polarization in 66cl4 and 67NR primary tumors. Aim of all animal models is to 
mimic human disease conditions. In order to investigate relation between patient survival rate 
and CD68, ARG1 and NOS2 macrophage markers gene expression Breast Mark online 
database was investigated. According to this database, there is no correlation between survival 
rate in breast cancer patient and expression of Cd68, Arg1and Nos2 genes. However, studies 
described function of TAMs in breast carcinogenesis (96-98). It has been claimed that higher 
number of TAMs do not always correlate with worse prognosis. However, different 
macrophage localization can correlate with patient survival (140). 
Brian Ruffell et al., 2012 expressed that CD68 is not a specific macrophage marker for human 
breast cancer (31). Therefore, there might be other macrophage markers that are more specific 
and upregulated in human breast cancer that also correlates with patient survival. Thus, this 
result does not deny the role of macrophages in breast tumor carcinogenesis. Assessing 
transcriptome data in this mouse model demonstrated differences in mRNA expression of these 
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macrophage markers in mouse breast cancer cells and primary tumors. Therefore, it was 
assumed that these markers could be used for localizing and characterizing infiltrated 
macrophages in this study. Generally, in order to increase accuracy of future human and mouse 
studies, more than one macrophage marker can be investigated.   
In contrary, there are studies that claimed expression of CD68 in tumor stroma correlates with 
reduced overall breast cancer survival (47, 81). It would be beneficial to investigate breast 
cancer as a whole, as its survival can depend on parallel factors. As it has been established, 
CD68+ cell density alone showed no statistical significance in overall survival. However, low 
CD8+ Tc and high CD68
+ correlates with reduced overall survival in basal like breast cancer 
(95). It is noticeable that results from these studies and breast mark is influenced by number of 
patients as well.  
Western blot analysis was performed in order to investigate macrophage infiltration within 
primary tumors. Therefore, protein expression of ARG1 and NOS2 in the 66cl4 and 67NR 
primary tumor was investigated. Expression of ARG1 in aggressive 66cl4primary tumor was 
detected while its expression in 67NR primary tumor and both cancer cell lines could not be 
observed. As it can be seen in the immune blot, expression of NOS2 was not detected in primary 
tumors. Transcriptome data analysis results correlates with the detection of NOS2 and ARG1 
in western blots of the tumor extracts. Based on transcriptome data, Arg1 is expressed higher 
in 66cl4 than 67NR primary tumor and Nos2 is low expressed in both primary tumors. It is 
notable that mRNA level does not necessarily correlates with protein levels. Movahedi et al., 
2010 have also stated higher arginase activity in TAMs in the mouse breast cancer model (132). 
This difference can be assumed as macrophages phenotypic variance within different primary 
tumors. Based on immune blot and transcriptome data analysis, it can be assumed that M2 
macrophages are higher infiltrated in 66cl4 primary tumors than 67NR. However, it needs more 
experimental support since expression of macrophage marker proteins could be too low to be 
detected in 67NR primary tumor by this technique. However, in order to compare protein 
expression of M1 macrophage markers within primary tumors, other markers such as CD74 can 
be chosen for future studies. 
As it has been mentioned, higher number of TAMs do not always correlate with worse 
prognosis. However, different macrophage localization can correlate with patient survival 
(140). Plethora of macrophages can be seen at margin of the mouse mammary tumors (141) and 
macrophages present in hypoxic area are more M2-like (142). Therefore, macrophage 
localization using immunofluorescence staining can lead to better comprehension of its function 
within breast tumor and can facilitate macrophage cognition. FFPE 66cl4 tumor sections were 
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stained for ARG1 and NOS2 antibodies and scanned with Odyssey scanner. Resolution of 
odyssey scanner is not high and does not enable distinguishing between cells (one pixel on a 
picture is about one cell). The same regions were stained for NOS2 and ARG1 over the sections 
and macrophages identification by immunofluorescence staining was not possible. Based on 
genotyping results, almost 60% of 66cl4 primary tumors constitute of tumor cells. Therefore, it 
was expected that some parts of the sections were not stained with macrophage markers. 
Nonspecific binding of primary antibodies and technical problems in sections preparation can 
cause errors in staining.   
As the previous staining technique was not specific for macrophage localization using odyssey 
scanner was not possible. Therefore, 66cl4 and 67NR primary tumor sections were stained for 
CD68 primary and fluorescent secondary antibodies. For this experiment, GFP tagged tumor 
cells were injected to the BALB/cfC3H mouse to facilitate discrimination between tumor and 
non-tumor cells. Thus, tumor cells would be detected with green florescent. No clear difference 
in staining between negative controls and the stained sections was observed.  
Working with confocal microscope needs practice and there are several technical details 
regarding microscope set up that can influence quality and resolution of the images. For 
instance, high gain value can generate pseudo-florescence signal and create false positive result. 
Fixation mistakes can cause cell dryness that would be seen as artifacts in the section.  
Due to the macrophages heterogeneity, even more than one marker cannot necessarily detect 
all the population (143). Thus, for future studies more than one macrophage markers should be 
chosen. Macrophages are distributed in normal liver and spleen (143); therefore, these tissues 
can be used as a positive control for future staining. However, this study was planned by the 
tissues and material that were accessible. 
 
4.3 RAW264.7 and IC-21 cells are not suitable in vitro models for studying 
interaction of 66cl4 breast cancer cells and macrophages 
Models giving chance of simplifying in vivo interactions, mimic in vivo environment in a co-
culture, and manipulate conditions. Interaction of tumor cells with its microenvironment can 
effect tumor growth and metastasis (21). Based on results of this study, it was assumed that 
macrophages are present in the 66cl4 primary tumors. An in vitro model enables studying 
interaction of tumor cells and macrophages in a simplified defined condition. Different cells 
can be used for this study; bone marrow-derived macrophages (BMDM), peritoneal 
macrophages and also Raw264.7 and IC21 cell lines.  
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RAW264.7 macrophages is a mouse-derived cell line that does not need any maturation 
procedure like BMDM. In addition, RAW264.7 macrophage cell line can be assumed as  “M0” 
and be polarized toward M1/M2 subtypes by different cytokines (131). Different polarization 
of RAW264.7 macrophages in the presence of the cancer cells or conditioned medium of tumor 
cells was investigated. Macrophages can be polarized to M1 in presence of IFN-γ plus LPS and 
to M2 macrophages in presence of IL4 (45). M1 maturation upregulate NOS2 and M2 
maturation enhance ARG1 expression (144).  
Studying interaction of RAW264.7 macrophages with 66cl4 primary tumors can lead to more 
understanding about aggressive growth of 66cl4 tumors and effect of released cytokines from 
breast cancer cells on macrophage polarization. Cultured cells that were treated with 
conditioned mediums of tumor cells were stained for ARG1 and NOS2 and were analyzed using 
confocal microscope. ARG1 positive staining was observed in the negative control, therefore, 
results are not comparative and trustable. A slight difference in RAW264.7 cells stimulated 
with IFN-γ and LPS was observed. Obtained results implies that more likely conditioned 
mediums could not effect RAW264.7 cells polarization. 
Immune blot analysis was performed in order to observe protein expression of NOS2 and ARG1 
on stimulated RAW264.7 with conditioned medium of 66cl4 and 67NR. Immune blot analysis 
demonstrated no expression in macrophage markers after stimulation with conditioned medium 
of 66cl4 and 67NR. However, RAW264.7 macrophages expressed NOS2 after stimulation with 
IFN-γ and LPS and the same trend was observed in immunofluorescence stained cells.  
Negative IL4 stimulation could not be due to un-bioactive recombinant cytokines because bio 
reactivity of cytokines was previously tested on BMDM by other member of the group. It is 
probable that expression of Nos2 and Arg1 genes are not high so it is hard to observe protein 
expressions on a blotted membrane. Therefore, mRNA expression of Cd74 and Nos2 as M1 
macrophage markers and ARG1 and Cd163 as M2 macrophage markers in co-cultures and 
stimulated cells with conditioned medium of 66cl4 and 67NR was investigated. For this step of 
study, cells were co-cultured in trans-wells in order to increase interaction of cells and probably 
observe changes in macrophage polarization in vitro.  
Expression of Cd74 was analysed due to the low Ct value. Statistical analysis demonstrated 
upregulation of Cd74 after stimulation with IFN-γ and LPS. Results from florescent stained 
cells and immune blot demonstrated M1 macrophage polarization after IFN-γ plus LPS 
stimulation. However, no significant up regulation of Cd74 mRNA expression in trans-wells 
and stimulated cells with conditioned mediums was observed.  
Discussion 
70 
Results from RT-qPCR assay demonstrated no mRNA expression of Nos2, Cd163 and Arg1 in 
samples. High Ct values can demonstrate absence of Nos2, Cd163 and Arg1 mRNA in cells. 
Results from mRNA expression level of Arg1 demonstrate nonspecific staining results from 
stained RAW264.7 cells stimulated with IL4 since ARG1 was expressed in all samples. Those 
results can be due to auto-florescence of the cells because when gene is not expressed, protein 
expression cannot be high. Gao S et at., 2014  demonstrated that Arg1 mRNA expression has 
increased after 12 hours stimulation with IL4 (10ng/ml) compared to unstimulated (145). 
Therefore, protocol can be improved by using more stimulation time points for further analysis. 
It can be assumed that these genes are not expressed in RAW264.7 cells stimulated with 
conditioned medium of 66cl4 and 67NR cancer cells or this technique is not sensitive enough 
for measuring mRNA expression in this assay. 
RAW264.7 macrophage cells have been used for designing a model for studying interaction of 
rat breast cancer cells with macrophages (146). However, based on the results of this study, it 
was concluded that RAW264.7 cell line is not suitable for modeling interaction of macrophages 
with 66cl4 breast cancer cells. Therefore, IC-21 macrophages were chosen to study interaction 
of macrophages with cancer cells. IC-21 is a C57BL/6 mouse adherent cell line that has been 
used for inflammatory models (147). IC-21 mouse macrophage cells were cultured with 
conditioned medium of breast cancer cell. No polarization toward M1 or M2 macrophages by 
immunoblot analysis using conditioned medium of 66cl4 and 67NR cancer cells was detected. 
Comparing IC-21 cells stimulation status with RAW264.7 macrophages demonstrated that  
IC-21 cells were less reactive to stimuli. Based on these results IC-21 cell line is not suitable 
for further investigation. 
RAW264.7 and IC-21 cells used for these analysis was obtained from CEMIR group and were 
with an unknown passage number. Therefore, unresponsive of RAW264.7 and IC-21 cells to 
stimulation can be due to the high passage number of these cells.  
It is notable that both the transformed cell lines RAW264.7 and IC-21 may have partially 
changed their signaling pathways during development. Therefore, these cell lines are less 
suitable for studying normal cells regulation. 
Parallel experimental analysis by other member of Bjørkøy group demonstrated that BMDM 
and peritoneal macrophages could be used for studying macrophage and breast cancer cells 
interaction. BMDM and peritoneal macrophages were polarization toward M1 or M2 by 
different stimuli and conditioned medium of 66cl4 and 67NR. Therefore, RAW264.7 and IC-
21 cell lines will not be used for further experiments. 
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Results from this study demonstrated that primary tumors stablished by two breast cancer cell 
lines 66cl4 and 67NR are heterogeneous and non-tumor cells can be polarized into these two 
primary tumors. The transcriptome data and immunoblot analysis suggests that more M2 
macrophages infiltrated within 66cl4 primary tumor than 67NR. Further aim was to investigate 
interaction of 66cl4 cancer cells and macrophages in an in vitro model by using RAW264.7 and 
IC-21 macrophage cell lines. Results obtained from his study does not recommend this two cell 
lines for future work. 
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5. Conclusion and future work 
Primary tumors established by two breast cancer cell lines 66cl4 and 67NR have different 
metastatic potential and represent a good model to study mechanisms that might underlay 
metastasis. Analyzing transcriptome data of cultured cells and primary tumors of 66cl4 and 
67NR gives valuable information regarding the sum of the cells in the primary tumors. Absence 
of mRNA expression of specific markers in the cell culture and higher expression in primary 
tumors can indicate possible infiltration of the host cells to the primary tumors. Genotyping of 
primary tumors can be used to estimate the number of non-tumor cells within primary tumors. 
As it has been calculated, about 40% of 66cl4 and 30% of 67NR primary tumors consist of non-
tumor cells that could account for the expression of markers in the tumor that were absent in 
the cell culture.  
Results of this study indicate more heterogeneity in 66cl4 than 67NR primary tumors. Based 
on transcriptome data and immune blot analysis of ARG1, it can be assumed that M2 
macrophages are higher infiltrated within 66cl4 primary tumor than 67NR. However, it has to 
be verified that ARG1 is not expressed by other cells of the tumors. Overall results 
demonstrated that M1 marker NOS2 is not detectable in tumor samples. 
To study tumor cell-macrophage interactions in the complex tumor microenvironment in more 
detail, it would be beneficial to establish an in vitro model with only two cell types. Culturing 
66cl4 and 67NR breast cancer cells with RAW264.7 macrophage cell line did not demonstrate 
any changes in polarization of the macrophages. In addition, no effect on RAW264.7 and IC-
21 cells after treatment of with conditioned medium of both cancer cells was observed. These 
results suggests that these two macrophage cell lines cannot be ideal models for studying this 
interaction.  
Based on results from Bjørkøy group, BMDM and peritoneal macrophages can be used for  
in vitro modeling of tumor stroma interaction. Future experiments should be focused on 
compounds secreted by 66cl4 tumor cells that contribute in macrophage recruitment and 
polarization. Therefore, conditioned medium of 66cl4 and 67NR cancer cells can be analyzed 
for different cytokines and chemokines by ELISA. Knocking out of these components in 66cl4 
tumor cells and studying their interaction with macrophages can also indicate the function of 
these components in tumor metastasis. Transcriptome data analysis can help choosing suitable 
targets and confirming results. 
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Further research should be aimed at investigating other M1 macrophage markers than NOS2 
by literature study and transcriptome data analysis. For further studies, better methods to 
visualize macrophages in primary tumors should be established. RNA in situ hybridization 
(ISH) RNA scope in particular, is a suitable technique that can be used for more accurate 
targeting different macrophage markers within primary tumors.
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 Appendix 
I  Cell types and markers that can be investigated in breast tumor  
Cell type Markers (Mouse)  Marker (Human) Reference 
Myeloid lineage 
Macrophages general marker Adgre1 F4/80 (21, 39, 134) 
Cd68 CD68 (47, 134) 
M1 Macrophages  Cd40, Fcgr1 CD40, CD64 (41) 
Cd74 MHCII (132) 
Nos2 NOS2 (134, 148) 
M2 Macrophages 
 
Arg1 ARG1 (66, 134) 
Cd163  CD163 (41, 148) 
Fibroblast  Vim VIM (19) 
Epithelial  Cd44, Cd24  CD44, CD24 (149, 150) 
Monocytes Csf1r CSF1R (39) 
Dendritic cell Itgax CD11c (21, 151, 152) 
Neutrophil Itgam CD11b (39) 
Tie-2-expresing monocytes(TEM) Cd14, Itgam CD14, CD11b (19) 
Myeloid derived suppressor cells 
(MDSCs)  
Itgam Cd11b (21, 32) 
Vessel endothelial  Cd34 CD34 (81) 
Mast cell Cd203c CD203c (21) 
Lymphoid lineage 
B cell Cd19 CD19 (21) 
T cell Itga6 ITGA6 (CD49f) (153)  
NK cell Ncr1 NCR1 (CD335) (21) 
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II Chromosome 1 sequence (base of primer and probe design) 
 
Name: 66-67chr1 
TCATGCTTGAGCCGCCGATGCTGCTGAAGGCACCGGCTTTGTTTGCAGGTAAAGCCACAGTCCCCAC
ACTGCAGGAGGGGCCGGGGGCCAGAGGCTGGGGATGCAGTGGGATGCCTCCGTTTTTGATGGAGC
CTCAGGNNNNNNNNNNNNGGAGCAGTGAATGGGCAGAGACCACAGTGCAGATCTCCAGACTTAA
GGGGGCAGCCCTGGGTCTGGTGAGTCCTCAGGGTCCTTTCCTGCTGACAGCTAAAGGGACATGTGG
GGCAGGAGAAGAGGGCACCCTTTTGCTTCTGAACCACAGCTGTGTCCCCATCACTAGGACTGGACTC
TGTACTTCCAGTATTCAGGAGGGTAGAGTCCCCATTGTTAAGAGGAAGCACAACTGCATGGGTCTGG
GGGC[G/A]CCCACGCTTTCTTTTCTGGCCACGCCCCCCTCTACAGCCTTCAGTCACATGAGAGGTAAT
AGAAGAAAGCCGAGAACAAAGGAATGTACACGAGCTGCAGTGAAACTTGCCTTGCTCAAAGTGGAA
CTTCTCAGAGGTCCCTGTGGGTAAGGAGTTTTCTGGTGGAGAGGTTGGGAAGTCAGAGGGTGTGGG
AAGAGGTTCCTCTACTCCTGGCCCCCCAGGGAGGTCAGAAGGAGCATCTTTTGGAAGCAAGAGCTCT
ACCTTTGATGGTAAAGGTGGGGGCTTCCTACTTTCAGCATCCTGTGAGGCTTGGTTATCTGGGAGCT
GAGGATGTAGAGTGGGAGAGACAGGTTTGGGCAAAGCCTTGTTCTTTTTGAGAAGAACAGGGCATT
TCTTCATC 
